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Introduction 

Chapter 1 
1.0 INTRODUCTION 
1.1 Percutaneous devices 
1.1.1 Permanent percutaneous devices 
A percutaneous implant can be defined as an object, made from a synthetic 
material, that permanently penetrates through a surgically created skin defect.1 
These devices provide a connection between the milieu interior and exterior of the 
body. There are several applications of percutaneous devices in medicine. For 
instance, they can be used for diagnostic purposes or direct monitoring of organ 
functions.2'4 Furthermore they are applied for the attachment of an external hearing-
aid or limb prosthesis.5"10 Probably the most important use of percutaneous devices 
is facilitating life supporting functions. Examples are dialysis catheters or power 
supplies for artificial heart assists.11"22 
The permanent skin penetration implicates the presence of a constant port 
d'entree for bacteria around percutaneous devices. The formation of a stable skin-
implant junction in the area where the implant protrudes through the skin, is of vital 
importance in determining their success. As described above, a variety of patients 
is dependent on a good functional percutaneous device. To understand more of the 
tissue reaction around percutaneous devices, a short review of natural percutaneous 
structures and normal wound healing processes will be given. 
1.1.2 Natural percutaneous structures 
Fingernails, hairs, feathers and horns appear to penetrate the epidermal seal, 
but they all originate from the bottom of an epidermal invagination into the dermis. 
Therefore, in these situations the continuity of the epidermal sheet is maintained. 
Only two structures indeed penetrate the epidermis and can be considered as natural 
percutaneous structures, i.e. teeth and antlers.1 
With exception of the Babyrussa swine, teeth usually perforate the gingiva 
(figure l).23 The gingiva comprises that portion of the oral mucosa that covers the 
alveolar jaw bone and surrounds the neck of the teeth. It consists of connective 
tissue and stratified squamous epithelium. The connective tissue of the gingiva 
contains collagen fibre bundles, the so-called gingival fibres.24 These fibres 
perpendicularly attach to the tooth, hereby tightly fastening the gingiva to the tooth. 
In combination with the periodontal ligament, the connective structure between 
tooth-root and alveolar jaw bone, they provide firmness and strength to the gingiva 
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to withstand mechanical stresses. At the perigingival passage, the gingival 
epithelium invaginates for approximately 1 mm forming the gingival sulcus. At the 
bottom of this sulcus, the epithelium is connected with the tooth by means of special 
cell structures, so called hemidesmosomes.24 
Figure 1: Schematic drawing showing the collagen fibre bundles 
(arrow) inside the connective tissue of the gingiva 
Antlers represent a different situation because they are annually renewed.1·23 
Each year the bone of the antlers penetrates the skin, putting them in a percutaneous 
position. Two mechanisms are described for the protection of the exit-site. The first 
mechanism is formed by the presence of a granular acellular substance originating 
from sebaceous glands, which is found in the epidermal sulcus. This substance 
deeply penetrates in the bone and surrounding skin, hereby creating an elastic 
junction. Secondly, comparable to the gingival fibres, perpendicular collagen fibres 
from the dermis penetrate the antler bone. Furthermore, the antler itself is firmly 
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anchored in the skull bone, allowing great stress upon the antlers without damaging 
the percutaneous organ-skin interface. 
1.1.3 Physiological wound healing processes 
The skin consists of two different layers: the epidermis and the dermis.25 
The cells of the epidermis mainly consist of keratinocytes, layered in an orderly 
fashion. Five distinct cell layers can be recognized in the epidermis: the stratum 
basale, spinosum, granulosum, lucidum and corneum. The cells of the stratum 
basale form a single layer and are columnar shaped. Most of the mitosis capacity 
of the epidermis is found in this layer. During reproduction, the basal cells are 
pushed outward while maturation and aging occurs. Keratinization of the cells, 
already starting in the basal cell layer, is completed when the cells reach the 
outermost layer of the stratum corneum. This process will take 15-24 days, 
depending on the location of the skin. The epidermis is dependent on the dermis for 
exchange of nutrients and gases, because it does not contain blood vessels. 
The dermis can be subdivided into the stratum papillare and reticulare and 
mainly consists of connective tissue containing collagenous and elastic fibres and 
connective tissue cells (fibrocytes and fibroblasts). Furthermore, blood vessels, 
lymphatic vessels and nerve endings are located in the dermis. Epidermal dérivâtes, 
i.e. sebaceous and sweat glands and hair follicles, invaginate into the dermis. These 
appendages can effectively assist in the epithelialization of wound surfaces. Finally, 
the dermis is connected with the underlying tissues by the so-called hypodermis. 
The hypodermal tissue mainly consists of connective and fat tissue and contains the 
large vessels for the dermal blood supply. 
If the integrity of the skin is disturbed, e.g. by trauma or surgery, the 
physiological mechanisms of wound heal ing start. The purpose of these mechanisms 
is to prevent invasion of infective agents and to destroy those that have already 
managed to intrude.1 Two phases in wound healing can be distinguished, i.e. the 
inflammatory phase and the repair phase (figure I).'26 Sometimes even a third 
intermediate phase, called the proliferative phase, is described.27 In summary, 
during the inflammatory phase which takes about three days, the following events 
occur: at disruption of the integrity of the skin, blood vessels are torn, while cells 
and connective tissue are broken. Subsequently, the wound bed fills with blood 
from the torn vessels followed by activation of blood coagulation while the platelets 
bind to the exposed collagen. The release of chemotactic substances by platelets and 
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injured cells and activation of the complement system by exposed collagen and 
extracellular ATP attracts inflammatory cells. These cells, mainly 
polymorphonuclear granulocytes and monocytes differentiating into macrophages, 
start ingesting fragments of injured tissue and bacteria. Furthermore, the 
macrophages release substances to stimulate replication of fibroblasts and 
myofibroblasts at the wound edges. Within 12 hours after the injury, the mitotic 
activity of the epidermis is enhanced.28 
Inflammatory 
Phase 
Repair 
Phase 
Injury 
1 
Coagulation platelets 
Complement activity 
I 
ι— Macrophages —ι 
Neovascular 
Growth 
Fibroblasts 
u Collagen synthesis 
l Î 
Collagen lysis 
— Remodelling 
— Healed wound 
Figure 2: Diagram showing the different 
phases of wound healing in soft tissue 
At approximately the third day, formation of collagen fibres by the 
fibroblast becomes histologically visible.27 In addition, a network of capillaries is 
formed to provide oxygen to support the fibroblast synthesis of collagen. In front 
of the newly formed collagen matrix, the macrophages still continue to phagocytize 
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the dead material hereby creating an environment for other fibroblasts to settle. This 
"module of repair" continues until the wound is closed. The tissue formed is called 
granulation tissue. Already at the sixth day of wound healing, maturation of the 
collagen fibres starts. By means of collagen synthesis and lysis, remodelling of the 
collagen network occurs. Meanwhile, myofibroblasts are responsible for wound 
contraction, hereby reducing the wound surface. Finally, the number of cells will 
decrease, leaving scar tissue behind. The functional characteristics of this newly 
formed tissue are less effective compared to the original tissue.27,28 The wound 
strength will never reach its original value and the scar tissue is nonelastic.1 
Parallel to the processes described above, the basal cells proliferate from 
the epidermal wound edges, growing in between healthy living tissue and dead 
coagulum.28 When the epidermal cells achieve mutual contact, horizontal 
proliferation is discontinued. This process is called contact inhibition.29 From there, 
further proliferation in a vertical direction occurs, resulting in thickening of the 
initial monolayer of epithelial cells. When this multilayered epidermis has 
completely undermined the crust, it will be expelled, resulting in visible restoration 
of the skin integrity. 
1.1.4 Wound healing around percutaneous devices 
Considering wound healing around percutaneous devices, two important 
phenomena in the natural wound healing processes should be emphasized. First, 
epidermal cells only proliferate on well-perfused connective or granulation tissue, 
not on dead or foreign material. Secondly, a percutaneous device is implanted in 
such a way that it partly protrudes the injured skin. This implicates that contact 
inhibition of the epidermal cells cannot take place. As a consequence, it can be 
supposed that all percutaneous implants eventually will be lost, caused by one of the 
major failure mechanisms, i.e.: 
- marsupialization: after insertion of the percutaneous device, the basal cells 
start to proliferate from the edges of the wound towards the implant. Inhibition of 
this proliferation will not occur because (1) the newly formed granulation tissue 
surrounding the implant is not able to inhibit the migrating epidermis and (2) 
contact inhibition of the epidermal cells can not occur. As a consequence, the 
epidermis will grow downwards, parallel to the implant surface between the less 
viable granulation tissue and the well perfused connective tissue (figure 3). The 
process will continue until the implant is surrounded by epidermis and is finally 
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extruded. During the process of marsupialization, the sulcus between the implant 
and migrating epidermis will be filled with dead cell material. 
Figure 3: The epidermis will grow downwards alongside the implant 
surface and eventually extrudes the percutaneous device. 
- avulsion: mechanical stresses applied on the percutaneous device causes 
breakage of tissue bridges at the level of the epidermis and dermis. Depending on 
the severity of these stresses, this leads to the formation of microhematomata. These 
microhematomata induce focal inflammatory processes and consequently loss of 
connective tissue. Both the inflammatory response and the presence of blood around 
the device are a fertile soil for bacteria and can therefore lead to infection with 
subsequent failure of the percutaneous implant.30 The mechanical stresses can be 
divided in two groups, i.e. intrinsic and extrinsic stress factors.31 Retraction of the 
scar tissue surrounding the exit-site and surface migration of the epithelium are 
considered to be intrinsic stress factors. They are directly related to tissue growth 
and cell maturation. The extrinsic stresses acting on the percutaneous device are 
defined as those forces applied either to the skin or the implant by the external 
environment. They are directed either laterally, axially or torsionally (figure 4). 
- infection: the sinus tract development around the device often creates an 
access for bacterial invasion into the cutaneous tissue. After insertion of the 
percutaneous device an initial superficial colonization around the exit-site occurs. 
Local conditions that allow bacterial invasion, such as trauma or pressure necrosis 
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at the exit-site, can then result in infection. In addition, several other factors will 
influence the occurrence of infection e.g. the surgical approach used for the 
insertion of the percutaneous device, bacterial contamination during surgery, the 
state of the host defense mechanism, the quality of postoperative care and the 
personal hygiene of the recipient.32 The risk of infection is also influenced by the 
diameter of the implant at the exit-site, the duration of implantation and the 
presence of clotting around the implant site. When infection occurs, the 
subcutaneous tissue will form a thick capsule, infiltrated with inflammatory cells 
around the infected implant. Most of these inflammatory cells are 
polymorphonuclear leucocytes. The epidermal migration is inhibited and located 
adjacent to the tissue capsule. When infection cannot be controlled, loss of 
connective tissue surrounding the percutaneous implant will occur, eventually 
leading to extrusion of the device. 
Figure 4: The extrinsic stresses can be directed 
(a) laterally, (b) axially or (c) torsionally. 
1.1.5 Percutaneous implant design 
As the failure modes mentioned above are related to the skin reaction to the 
implant, the formation of a stable skin-implant junction may be the major factor in 
determining the success of percutaneous devices.31 Two factors are considered to 
be responsible for the formation and maintenance of an effective skin/implant seal: 
(1) chemical and physical properties of the implant materials 
(2) mechanical stresses, generated at the percutaneous implant-skin 
interface by the relative movement between implant and skin. 
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Considering the influence of the physico/chemical properties, first some 
general remarks on the application of so-called biomaterials for implant 
manufacturing have to be made. The general accepted definition of biomaterials is: 
"Biomaterials are nonviable materials used in a medical device, intended to interact 
with a biological system".34 This interaction can be divided into two aspects, i.e. 
the host response to the material and the material response to the living tissue. The 
host response can be defined as "the reaction of a living system to the presence of 
a material" and the material response (biocompatibility) as "the ability of a material 
to perform with appropriate host response in a specific situation". 
Materials used for the construction of percutaneous implants can be 
classified as: 
metals: mainly stainless steel, titanium and titanium alloys are used. 
Metals are stiff and strong and are covered by an oxide layer. The stability of the 
oxide layer determines the corrosion resistance of the metal. Compared to stainless 
steel, it is known that the surface of implants consisting of titanium and its alloys 
is surrounded by a highly adherent and protective oxide film.33"37 In contrast to 
stainless steel, released ions of these metals will form electroneutral hydroxides and 
oxides leading to a good tolerance.3840 
ceramics: similar to metals ceramics are strong, but on the other hand 
brittle. Consequently, implants manufactured from these materials can not be 
heavily loaded. Several researchers have used the calciumphosphate ceramic 
hydroxyapatite for the manufacturing of percutaneous devices.41'42 Furthermore 
alumina ceramic43 and carbons44·45 were applied. 
polymers: polymers are available with a wide variety of mechanical and 
physical properties. The additional advantage of polymers is that they can be 
formed with relative ease in the desired shape, at low cost. However, in clinical 
application, limiting factors in the use of polymers are lack of tissue compatibility 
(including toxicity) and lack of resistance to the biological environment.46 
Frequently used polymers in percutaneous devices are polysiloxanes (Silicone), 
polyethylene terephthalate (Dacron®), polyurethane and polytetrafluoroethylene 
(Teflon®). 
In addition to their bulk characteristics, the surface properties of an implant 
can also influence the final tissue reaction. In vitro experiments have shown that the 
surface free energy of a material can have effect on cellular attachment and 
growth.47 Furthermore, cellular behaviour (in terms of cellular orientation and 
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migration) can be influenced by changing the geometric surface properties.48"51 
Besides these physical surface properties, the chemical surface composition is an 
important factor. For example silver films have been applied on catheters because 
of their antimicrobial activity52"54 and titanium coating was used to improve the 
tissue reaction to Dacron® velour implants.55 Also the use of biological types of 
coating have been reported. Autologous fibroblasts, cultivated on the percutaneous 
part of the device, produced and deposited collagen which was demonstrated to 
improve the tissue reaction.13·56"59 
Mechanical stresses are another cause for percutaneous implant failure. To 
reduce these interfacial stresses, several solutions have been investigated. In several 
publications it was demonstrated that skeletal attachment of a percutaneous implant 
favoured the maintenance of the percutaneous passage.33-60"62 However, in most 
cases were percutaneous conduits are indicated, solely soft-tissue anchored systems 
can be used. For instance in peritoneal dialysis, the percutaneous implant has to be 
inserted in the highly mobile tissue of the abdominal wall. To find a solution for 
this application, most designs of percutaneous devices were provided with a micro-
or macroporous cuff or flange to anchor the implant.9·11·14-17·30·32·45·55·63-71 The purpose 
of the porosity is to allow ingrowth of connective tissue, resulting in a strong 
mechanical link with the device. Unfortunately, almost all designs eventually failed, 
due to the inability to obtain matured, well-vascularized connective tissue inside the 
pores of the anchor. Instead, the porosity was filled with inflammatory cells. 
There appears to be a significant correlation between the severity of the 
inflammatory reaction and the lack of connective tissue maturation: the tissue 
contains immature collagen bands, while no decrease of the cellularity appears.30 
Consequently, the epidermis follows the immature connective tissue into the pores. 
This process is called permigration (figure 5). How the basal cells of the epidermis 
penetrate this connective tissue is still an unknown process. Two mechanisms have 
been proposed. First, the epidermis follows the direction of least resistance between 
the inflammatory and the healthy connective tissue. Second, basal cells can 
penetrate by enzymatic lysis.72 This second mechanism is supported by the 
observation that collagenase activity is present in epidermal cells.73 
Finally it has to be noted that in the few successful implants, tissue necrosis 
above the rim of the subcutaneous anchor occurred also, resulting in extrusion and 
failure of the implant.74 
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Figure 5: The epidermis follows the immature connective tissue 
into the pores hereby gradually extruding the percutaneous device. 
1.2 Peritoneal dialysis 
1.2.1 History of peritoneal dialysis 
In patients with chronic renal failure, the amount of functioning nephrons 
is significantly reduced. If the excretory function of the kidneys decreases below 5-
10%, the phase of end-stage renal failure has been reached. Renal replacement 
therapy is necessary to survive from this condition. A renal transplantation is the 
most favourable option. Unfortunately not all patients can receive a donor kidney 
because (1) no sufficient number of donors is available resulting in a long waiting 
time for most patients and (2) patient-related conditions can restrict the indication 
to perform a transplantation. Therefore, chronic dialysis is often the only available 
treatment modality. The currently applied major types of chronic dialysis are 
intermittent haemodialysis (HD) and continuous ambulatory peritoneal dialysis 
(CAPD). 
The majority of patients on HD are treated in hospital three times a week 
for approximately 4 hours. For this treatment, an access route to the bloodstream 
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has to be created to connect the patient with the dialysis apparatus. Inside this 
apparatus, an exchange of fluid and metabolic products takes place between blood 
and dialysate alongside a semipermeable membrane. In this way, the function of the 
impaired kidneys can be compensated. 
An alternative for the treatment of patients with end-stage renal failure is 
peritoneal dialysis (PD). The method of PD is based on the capacity of the 
peritoneum to exchange fluid and metabolic products, hereby functioning as a 
semipermeable membrane. To achieve this, dialysis fluid has to be instilled in the 
abdominal cavity through a peritoneal access device. The dialysis capacity of the 
peritoneum was first described by Ganter in 1923.75 He showed that the ureum 
concentration of a saline solution, infused into the peritoneal cavity of uraemic 
guinea pigs, became close to the blood concentration. After several exchanges of 
the saline solution, the condition of the animals even improved. Thereafter, small 
groups of patients were treated with PD.76"79 A review of the literature between 
1923 and 1948, showed that of 63 patients with reversible renal diseases, 32 
patients fully recovered.80 These promising clinical results, resulted in acceptance 
of PD as an adequate therapy for patients with acute renal failure.81 
The first catheters used to create access to the peritoneal cavity were 
originally designed for other purposes, like oxygen supply or gastric tubing. They 
were made of polyethylene or polyvinyl chloride.82·83 However, frequent kinking of 
the catheters and blockage by the omentum made the dialysis procedure a 
complicated treatment. Despite these problems with the creation of suitable access 
to the abdominal cavity, PD was still considered to be an appropriate alternative for 
HD. Therefore, PD was started to be used as regular treatment in patients with 
chronic renal failure in 1962. On the other hand, as these patients need long-term 
treatment, the necessity for easy and comfortable access to the abdominal cavity 
increased. The devices newly designed,84"88 mostly consisted of two parts: (1) a 
percutaneous access device implanted in the abdominal wall and (2) the dialysis 
catheter, that can be inserted and removed through the percutaneous part. The 
access devices were made of teflon, silicone or polyvinyl chloride (figure 6). In 
between each dialysis treatment, the dialysis catheter was removed and the 
percutaneous access was closed by a cap. Unfortunately, this type of design ended 
in failure because it permitted easy access of bacteria to the peritoneal cavity, 
resulting in peritonitis. 
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Figure 6: The catheter is inserted through the 
access device at each dialysis treatment. 
To solve this problem, two alternatives were suggested to create peritoneal 
access: (1) the repeated puncture technique,""*2 and (2) the use of a subcutaneous 
access device. For example, Gotloib91·94 used a small semirigid Teflon® tube, 
leading directly to the peritoneal cavity. The tube had a funnel-shaped head which 
was situated subcutaneously and allowed easy introduction of a dialysis catheter. By 
means of a stylet, the skin was pierced under local anaesthesia to introduce this 
dialysis catheter. In each patient, two implants were inserted to allow alternate use 
of the overlying skin areas. Another type of subcutaneous access device consisted 
of a subcutaneous reservoir connected to an intraperitoneal^ situated silicone tube 
(figure 7).95 A large needle was used to puncture the reservoir for the exchange of 
dialysis fluid. In both alternative peritoneal access methods, the patient had to visit 
the clinic two or three times a week for dialysis. Despite a decline in the peritonitis 
rate, practical problems were responsible for a limited application of these 
techniques. The procedure was too time-consuming for the physician to be used on 
a larger scale. Furthermore, complications of the repeated puncture technique like 
bowel or urinary bladder perforation were reported. 
With the introduction of the silicone catheter provided with a subcutaneous 
anchor,9^99 the dialysis catheter could remain in situ for longer periods of time. The 
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materials used for the subcutaneous anchor mostly consisted of Teflon® or Dacron® 
velour. The development of the so-called Tenckhoff catheter11 was responsible for 
wide acceptance of chronic peritoneal dialysis, probably because the design and 
insertion procedure are simple. This last catheter is provided with two Dacron® 
velour cuffs, one located in the subcutaneous tissue and one positioned at the 
peritoneum (figure 8). The designed function of these Dacron® velour cuffs is to 
close the subcutaneous sinus tract to prevent bacterial invasion. 
Figure 7: A subcutaneous access device. 
1.2.2 Clinical application of CAPD 
With the development of a suitable catheter, research to optimize the PD 
technique progressed. This led to the development of the so-called equilibrium 
peritoneal dialysis technique, first described by Popovich and Moncrief in 1976.10° 
Later, the name of this dialysis method was changed to continuous ambulatory 
peritoneal dialysis or CAPD.101 The technique of CAPD is based on a constant 
removal of fluid and waste products: four times each day, two litres of dialysate 
were exchanged intraperitoneally. In between the exchanges, the patient can 
continue his normal activities while there is a constant removal of waste products 
23 
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from the body. From a physiological point of view, CAPD is the preferred method 
and eventually the most common form of home dialysis. 
Figure 8: The Tenckhoff catheter consists of a silicone tube 
provided with two Dacron® velour cuffs. 
In addition, other advantages of CAPD compared to haemodialysis are: 
1. the patient is not permanently dependent on hospital and staff because 
treatment takes place at home. Mainly because of this reason, peritoneal 
dialysis should be the method of choice for the majority of children with 
end-stage renal failure.102 
2. CAPD is better tolerated in patients with cardiovascular disease, like left 
ventricular hypertrophy or carotid artery disease, because the blood 
pressure is usually better controlled.103"106 Also, patients on CAPD have 
fewer risk factors for progressive increases in left ventricular mass 
compared to HD patients.107 
3. the degree of anaemia in CAPD patients is less severe than in HD 
patients.106108 Furthermore, CAPD patients respond better to recombinant 
human erythropoietin, thereby improving exercise tolerance and 
decreasing the degree of fatigue.108 
4. for diabetic patients on CAPD, residual renal function is better preserved 
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and metabolic control is more convenient.103 
5. there is no need for a vascular access with the accompanying necessity 
for anticoagulant drugs.105 
6. because there is a constant removal of waste products and redundant 
fluid, the diet of С APD patients is less strict.106109 
7. the method is relatively cheap and after two weeks of training, most 
patients can perform the exchange technique independently.105109 
1.2.3 Specific problems in peritoneal dialysis 
Despite the benefits of CAPD mentioned above and the introduction of new 
catheter designs, the efficacy of this technique is still hampered by severe 
problems.110 Both infection of the percutaneous exit-site of the catheter and 
peritonitis are serious complicating factors, often resulting in discontinuation of 
CAPD. Furthermore, a relationship is supposed between recurrent peritonitis and 
access problems.109111112 Prevention of these exit-site infections will reduce the 
number of peritonitis episodes and improve the quality of life of patients treated 
with CAPD.1 1 0 1 1 3 Therefore it can be concluded that access problems are the current 
Achilles' heel in peritoneal dialysis. Both exit-site infections and peritonitis are 
responsible for substantial morbidity and sometimes even mortality. 
Several risk factors have been described for developing an exit-site 
infection, such as poor hygiene, traction on the catheter and reduced immunologic 
defense.112 Also the design of the percutaneous access device can be of influence on 
the complication rate. Recently, Gokal et alu* emphasized again that a new access 
device for CAPD should be developed, giving special attention to the materials 
used, to avoid foreign body response as seen with the Dacron® cuffs of the 
Tenckhoff catheter. Furthermore, the design of the subcutaneous anchor should be 
able to eliminate motion at the exit-site and in this way reduce the number of 
infections. 
1.3 Aim 
Taking the above described considerations into account, the aim of this 
study was to investigate the application of a percutaneous device, provided with a 
titanium fibre mesh, to create access to the abdominal cavity as necessary in 
peritoneal dialysis. The choice of the material and design was based on (1) 
fundamental studies on percutaneous implant behaviour as performed by Jansen et 
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a/ 3 3 · 4 2 6 1 1 1 5 and (2) the good tissue performance of the titanium fibre mesh structure 
in bone as first used for application in orthopaedic surgery."6117 Extrapolation of 
these results led to the use of the flexible porous titanium fibre mesh structure for 
the fabrication of soft tissue anchored percutaneous devices.118 The implants 
consisted of a subcutaneous fibre mesh and a solid percutaneous component. In 
addition to the design of the implant, a two-stage surgical procedure was used for 
the insertion of the device. During the first surgical session, the subcutaneous 
implant part was inserted. After a healing period of 3 months, the percutaneous part 
was placed. It appeared that the titanium fibre mesh materials, in combination with 
the surgical technique, evoked minor adverse tissue response. 
Chapter 2 will give a description of the access problems of patients on 
С APD as found at the Department of Medicine, Division of Nephrology, University 
Hospital Nijmegen, The Netherlands. An in vitro experiment, as described in 
chapter 3, determines the corrosion behaviour of titanium and stainless steel 316L 
fibre meshes under various circumstances. Chapter 4 analyses histological and 
histomorphometrical data of the subcutaneous tissue reaction to the Dacron® velour 
cuff of the currently used peritoneal dialysis catheter versus the titanium fibre mesh. 
Chapter 5 describes an experimental study in rabbits on the tissue reaction to the 
percutaneous device, consisting of the titanium fibre mesh anchored implant. In 
chapter 6, the surgical technique to insert the titanium mesh percutaneous device is 
evaluated, giving special attention to the possibility of inserting the device in a one-
stage surgical procedure. In chapter 7, the length of the intervening healing period 
between the first and second surgical procedure is investigated. In an experimental 
study in rabbits the subcutaneous healing period varies from 5 till 10 weeks. 
Chapter 8 describes the tissue reaction to the titanium fibre meshes in goats with an 
implantation period varying from 1 till 6 weeks. In chapter 9 the final conclusions 
are summarized and recommendations towards future experiments are outlined. 
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Access related problems 
with continuous 
ambulatory peritoneal 
dialysis 

2.0 ACCESS RELATED PROBLEMS WITH CONTINUOUS 
AMBULATORY PERITONEAL DIALYSIS 
2.1 Introduction 
Patients with end-stage renal failure can be treated in several ways. The two 
most common therapeutic modalities are haemodialysis (HD) and continuous 
ambulatory peritoneal dialysis (CAPD). In HD, blood purification takes place 
outside the human body by using a filter process, based on gradient differences of 
metabolites between blood and dialysis fluid. The method of peritoneal dialysis is 
based on the capacity of the peritoneum to exchange fluid and metabolic products. 
To achieve this, dialysis fluid has to be instilled in the abdominal cavity through a 
permanent percutaneous access device. This implies that a constantly open 
connection exists between the peritoneal cavity and exterior. In general, for most 
patients dialysis is a temporary measure in expectation of a kidney transplantation. 
For others, dialysis will be their only renal replacement therapy. Therefore it is 
important to optimize this treatment for both patient and physician. 
CAPD has some important advantages compared to haemodialysis: 
1. the patient is not permanently dependent on hospital and staff because 
treatment takes place at home. Mainly because of this, peritoneal dialysis 
remains the method of choice for the majority of children with end-stage 
renal failure.1 
2. CAPD is better tolerated in patients with cardiovascular disease, such as 
left ventricular hypertrophy or carotid artery disease.2-3 Also, patients on 
CAPD have fewer risk factors for progressive increases in left ventricular 
mass, compared to HD patients.4 
3. the degree of anaemia in CAPD patients is less severe than that in HD 
patients.5 
4. CAPD patients respond better to recombinant human erythropoietin, 
thereby improving exercise tolerance and decreasing the degree of fatigue.5 
5. for diabetic patients on CAPD, residual renal function is better preserved 
and metabolic control is more convenient.2 
Despite these benefits, the efficacy of CAPD is hampered by severe 
problems, such as infection of the percutaneous exit-site of the catheter.' Peritonitis 
is also a complicating factor, although introduction of the so-called "flush before 
fill" Y-set system has decreased the number of peritonitis episodes.7 This Y-set 
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system together with the bag of dialysis fluid is connected to the peritoneal dialysis 
catheter and makes it possible to flush the tubing of the system before the dialysis 
fluid is instilled in the abdominal cavity. The infectious complications described 
above can lead to bacteraemia and sepsis. 
In the Netherlands, peritoneal dialysis was first introduced in 1980. 
Thereafter CAPD has gained more popularity and the number of patients on 
peritoneal dialysis grew constantly. In 1993, 3470 patients were treated with one 
of the dialysis methods in the Netherlands. In 28% of these patients peritoneal 
dialysis was the choice of treatment.8 
In the University Hospital in Nijmegen the peritoneal dialysis program 
started in October 1981. This study will describe the demographic data of all 
patients included in the program, together with a thorough description of the 
observed complications. 
2.2 Patients and Methods 
2.2.1 Patients 
From October 1981 till February 1994, data were collected from 118 
patients treated with CAPD in the Nephrology Department at the University 
Hospital Nijmegen. Until December 1992 the records were reviewed 
retrospectively; thereafter prospective data were collected. The 118 patients were 
responsible for 147 CAPD periods. A CAPD period was defined as the period 
between the moment the patient was trained to perform CAPD and discontinuation 
of dialysis treatment, independent of the reason for discontinuation. Patients 
transferred to another dialysis centre were excluded from this study at the moment 
of transferral. 
2.2.2 CAPD technique 
In the total group of 118 patients, 166 catheters were inserted during the 
period of investigation. With the exception of four catheters, only double-cuffed 
Tenckhoff catheters were used. This type of catheter consists of a silicone tube with 
two porous polyethyleneterephtalate (Dacron® velour) cuffs attached to it by means 
of medical grade silicone glue. 
The catheters were placed by the Surgical Department of our hospital. 
Before surgery, the position of the exit-site was determined, considering the 
anatomy of the patient's belly. According to a surgical protocol and taking the 
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patient's preference into account, the catheter was placed under general or local 
anaesthesia. A median or paramedian incision was made. The distal cuff was 
situated between the peritoneum and the fascia of the rectus muscle. A tunnel was 
created through the different tissue layers, leading the catheter to the subcutaneous 
tissue. There, the proximal cuff was placed two to three centimetres away from the 
exit-site. In most of the patients, the exit-site was situated above the level of the 
umbilicus and cranial to the tunnel. 
After surgery, a sterile gauze was applied to cover the wound and to fix the 
catheter. The abdomen was flushed with dialysis fluid (1.5% glucose) until the fluid 
was clear. The dressing applied at the operation theatre remained in place for 
several days unless signs of bleeding or leakage of dialysis fluid occurred. 
Thereafter, the exit-site care consisted of a daily checkup, together with application 
of povidone-iodine and a sterile gauze at the exit-site. When the exit-site was 
healed, showering and cleaning the body with soap was recommended. According 
to the patient's preference, covering of the exit-site and anchoring of the catheter 
consisted of a gauze, adhesive dressing or no coverage at all. Whenever possible, 
dialysis was started after a postoperative healing period of at least three weeks. 
Each patient performed 4 exchanges of the dialysis fluid per day. From 1981 till 
1989, the standard spike system was used by patients performing CAPD. Starting 
in 1990, all patients were transferred to a disconnect Y-set system. 
2.2.3 Evaluation and definitions 
Each clinical visit and whenever the patient reported catheter-related 
problems, the exit-site and the tunnel of the catheter were investigated. From 
December 1992, the appearance of the exit-site and tunnel were extensively 
registered. The parameters used were skin colour, presence of exit-site drainage, 
appearance of granulation tissue, pain around the exit-site and skin retraction. Three 
physicians were responsible for these observations. The parameters were scored 
using a systematic list (table 1), whereby a high total score represented a bad 
looking exit-site. In this way we compared the clinical follow-up with the 
appearance of exit-site infections (ESI). 
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Table 1. Registration form of the clinical parameters as used at the outpatient clinic 
to evaluate the exit-site ot the catheter. 
CLINICAL PARAMETERS 
Date of visit to outpatient clinic 
Exit-site 
* Skin colour 1 normal 
2 pink 
3 red indurated 
* Painful 1 no 
2 yes 
* Drainage 1 no drainage/crust formation 
2 hardly exudate around exit-site 
3 exudate around catheter 
* Granulation tissue 1 absent 
2 hardly present 
3 hypertrophic granulation tissue 
* Skin retraction 1 absent, skin lies closely around catheter 
2 present, cuff partly visible 
3 cuff completely visible 
The ESI was defined as erythema and/or drainage around the catheter. A 
subsequent infection was diagnosed if the patient did not use antibiotic drugs for at 
least two weeks and the exit-site appeared normal before infection. A tunnel 
infection was defined if erythema and/or tenderness over the subcutaneous catheter 
tunnel existed. When the exit-site and/or tunnel was suspected of infection, a 
standard swab culture was taken. Thereafter oral antibiotic treatment was started. 
The antibiotics used were variable and generally consisted of flucloxacillin or 
Cotrimoxazol. According to the results of the culture, the antibiotic therapy was 
38 
Chapter 2 
changed if necessary. Until 1992 the antibiotics were usually given for 14 days. 
From 1992 antibiotics were given for an additional four weeks if, after two weeks 
of therapy, the exit-site was not properly healed. In the presence of an abscess, 
surgical drainage was carried out. ESIs not responding to antibiotic treatment 
necessitated removal of the catheter. 
When a patient had severe abdominal discomfort or cloudy dialysis fluid, 
both possible symptoms of peritonitis, the dialysis fluid was sent for microbiological 
examination including a Gram stain, a culture and a cell count. When more than 0.1 
* 109 leucocytes/1 were present, initial treatment with antibiotics was started 
according to the results of the Gram stain. Before 1988, the initial antibiotic 
treatment usually consisted of gentamicin combined with cephalothin, and was 
administered intraperitoneally until at least three consecutive cultures were sterile. 
Subsequently, a course of oral antibiotics was given to complete the fourteen days 
of therapy. If the peritonitis was not responding to this treatment, vancomycin was 
given instead. From 1988 the initial drug therapy consisted of cephradine orally or 
intraperitoneally when the Gram stain showed no or a gram-positive microorganism. 
If possible, the patient was treated in the outpatient clinic. Again vancomycin was 
most commonly used if the peritonitis did not respond to cephradine. The catheter 
was removed whenever peritonitis could not be treated properly or when several 
episodes of peritonitis occurred within a short period of time. 
2.2.4 Data recording 
The data recorded included time on dialysis, catheter removal and 
occurrence of CAPD related infections, together with the culture results responsible 
for these infections. Based on these data, infection rates, defined as the total number 
of infections each year divided by the total time on peritoneal dialysis in that year, 
were calculated. Statistical analysis of the infection rates was performed using the 
non-parametric test according to Wilcoxon. Chi square analysis was used to 
compare proportions involving demographic data. Statistical significance was 
accepted at ρ < 0.05. 
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2.3 Results 
2.3.1 General information 
The age at starting a new CAPD period varied from 17 to 84 years, with 
a mean age of 43. During the period of investigation there was a total of 2600 
CAPD months, with a range of 2 days to 73 months and a mean of 17 months per 
patient. The ratio between males (57%) and females (43%) was constant throughout 
the period of investigation. In our group of patients 18 were insulin-dependent 
diabetics (15%). 
2.3.2 Exit-site infections 
During the period 1982 to 1993, 182 episodes of ESI were recorded in 61 
patients. In figure 1, the rates of ESI (± SD) per patient-year are outlined. It 
appeared that the overall infection rate was 0.80 ± 0.36 per patient-year. Figure 
2 shows the results of the microbiological cultures. In 11 % the results of the culture 
could not be found in the patients records and in two ESIs the culture was sterile. 
Most ESIs are caused by a gram-positive microorganism (80%), and 90 % of these 
are Staphylococcus aureus. In 8%, a gram-negative organism was responsible for 
the exit-site infections. Five ESIs were caused by Pseudomonas aeruginosa and one 
by Candida albicans. 
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Figure 1: The infection rates of exit-site infections 
and peritonitis per patient-year. 
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Figure 2: The microorganisms responsible for the exit-site infections 
during the period of investigation. 
From December 1992 on, 255 observations of the clinical appearance of the 
exit-site and tunnel took place. Because skin colour, drainage and the appearance 
of granulation tissue were the most important parameters, figure 3 shows only the 
scores of these parameters in patients with and without infection. It appeared that 
an ESI was diagnosed when the clinical score was 5 or higher. On the other hand 
a clinical score of 5 or 6 did not always lead to the diagnosis ESI. 
no Infection 
1-в кз pre inf 
0-1 wk» pre inf 
1-6wk» post ¡nf 
CLINICAL SCORES 
DRAINAOE. ORANULATION AND SKIN COLOR 
(ZZI 
PERCENTAGE OF OBSERVATIONS 
Figure 3: The clinical scores in the bar graph represent the appearance 
of the exit-site in patients without an exit-site infection, one to six weeks 
before infection, the moment of diagnosis and one to six weeks after diagnosis. 
A high score in the graph represents a bad looking exit-site. 
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2.3.3 Peritonitis 
In 73 patients there were 276 episodes of peritonitis. Figure 1 shows the 
number of peritonitis per patient-year. Throughout the years the peritonitis rate (± 
SD) per patient tended to decline. The average peritonitis rate was 1.36 ± 0.51 
episodes/patient-year. Before transfer to the Y-set dialysis system in 1990, the mean 
peritonitis rate was 1.59 ± 0.40 episodes/patient-year compared to 0.89 ± 0.39 
episodes/patient-year after the introduction of the Y-set. Statistical analysis showed 
a significant difference between these peritonitis rates (p<0.01). The population 
before and after the transfer to the Y-set system was not significantly different. 
Figure 4 shows the distribution of the number of peritonitis episodes per patient 
while on CAPD. Statistical analysis revealed that the number of patients without 
peritonitis was significantly higher after introduction of the Y-set system (p < 0.01). 
NUMBER OF PERITONITIS EPISODES 
BEFORE AND AFTER INTRODUCTION Y-SET 
all patients 
before Intro 
after Intro 
0 episodes 
• ^ • H 1 episode 
V^mtA 2 episodes 
I I 3 or more 
episodes 
PERCENTAGE OF PATIENTS 
Figure 4: The number of peritonitis episodes registered during a CAPD-period 
before and after the introduction of the "flush before fill" Y-set system. 
Most infections were caused by gram-positive microorganisms (64%) 
(figure 5). Among this group, the most common microorganisms were 
Staphylococcus epidermidis (45%) and Staphylococcus aureus (34%). In 21% 
various other species of gram-positive microorganisms were determined. In 13% 
of the cultures gram-negative organisms were found, in 20% of the cases the culture 
was sterile and in 1.5% the results of the cultures could not be found in the patients 
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records. Only two peritonitis periods were caused by Pseudomonas aeruginosa. In 
addition, Candida albicans was responsible for the peritonitis in four patients. One 
patient died 6 days after candida peritonitis became evident. In the other three 
patients, the catheters were removed within one week after diagnosis because of 
lack of response to antimycotic drug treatment. These patients were transferred to 
haemodialysis. Nevertheless, one of these patients died two weeks after removal of 
the catheter, while the other two patients fully recovered. 
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Figure 5: The microorganisms responsible for the peritonitis 
during the period of investigation. 
Analyzing the various most common antibiotic treatment regimens (table 2), 
the combination of gentamicin and cephalothin was successful in 83% of 111 
episodes of peritonitis. In 9% the therapy had to be changed into another antibiotic 
regimen. The catheter had to be removed in 8 patients (7%) and one patient died 
during peritonitis. Cephradine was successful in only 60% of 65 peritonitis 
episodes. In 34% a change to another antibiotic drug was made. In three patients 
(5%) the catheter was removed and one patient died during the treatment. Statistical 
analysis showed a significant difference between the adequacy of the consecutive 
antibiotic treatments (p < 0.01). Despite these figures, the mean period of admission 
to the hospital for patients initially treated with gentamicin and cephalothin was 10.2 
days compared to 5.6 days for cephradine (p<0.01). 
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Table 2. The number of peritonitis episodes treated with the most common 
antibiotic treatment regiments. 
Gram positive 
Genta micin/cephalothin 
cephradine 
vancomycin 
Gram negative 
Gentamicin/cephalothin 
cephradine 
vancomycin 
Negative culture 
Gentamicin/cephalothin 
cephradine 
vancomycin 
Total 
Gentamicin/cephalothin 
cephradine 
vancomycin 
uncomplicated 
64 
30 
18 
uncomplicated 
9 
1 
1 
uncomplicated 
19 
8 
12 
uncomplicated 
92 
39 
31 
removal' 
6 
2 
6 
removal 
2 
0 
0 
removal 
0 
1 
2 
removal 
8 
3 
8 
switch2 
2 
13 
3 
switch 
3 
9 
1 
switch 
5 
0 
0 
switch 
10 
22 
4 
switch and removal 
0 
0 
1 
switch and removal 
0 
0 
1 
switch and removal 
0 
0 
0 
switch and removal 
0 
0 
2 
died 
0 
0 
0 
died 
1 
1 
0 
died 
0 
0 
1 
died 
1 
1 
1 
total 
111 
65 
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Note: in 54 peritonitis episodes, other antibiotics were used and therefore left out of consideration in this table. 
1
 Removal of the catheter,2 switch to another antibiotic therapy 
In this survey, 54 patients had no ESI in their medical history. Among these 
patients, 27 had one or more episodes of peritonitis (50%). In 60 patients having 
one or more ESIs, 46 patients (77%) had one or more episodes of peritonitis 
(p<0.01). Four patients were excluded from this calculation because their clinical 
follow-up was considered to be too short (less than one month). 
Catheter infection preceded peritonitis in 54 episodes (20%) of peritonitis. 
In 41 of these episodes, the same microorganism was also responsible for the ESI 
or one of both cultures was sterile. In 31 episodes Staphylococcus aureus was 
present. Before the introduction of the Y-set, only 12.9% of all peritonitis episodes 
were catheter infection-associated. After the introduction of the Y-set, 20.3 % of the 
peritonitis periods were catheter infection-related. However, statistical testing 
showed that this difference was not significant. 
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2.3.4 Catheter removal 
In 50 cases an infectious component was responsible for the removal of the 
peritoneal catheter, i.e. 18 episodes of peritonitis appeared to be recurrent or 
unbeatable, in 16 cases the ESI was not responding to antibiotic treatment as 
described before and 16 times an ESI together with peritonitis could not be treated 
properly. Inflow and outflow problems were the cause of the removal of 9 
catheters, while in two patients intestinal problems caused so much discomfort that 
we decided to discontinue of peritoneal dialysis and remove the catheter. Three 
patients stopped because of insufficient dialysis capacity of the peritoneum and two 
patients removed their own catheter during severe illness and disorientation. One 
patient discontinued peritoneal dialysis because of leakage of dialysis fluid in the 
abdominal wall and in one patient the necessity for dialysis treatment disappeared 
temporarily. In 52 CAPD-periods, the catheter could be removed after a successful 
transplantation procedure. At the end of the investigation period, 19 patients were 
still performing peritoneal dialysis. During the follow-up period three patients 
transferred to another dialysis centre. Twenty-four patients died during peritoneal 
dialysis treatment, 5 during a peritonitis episode. 
2.4 Discussion 
Peritoneal dialysis has some important advantages over haemodialysis. 
Unfortunately, access problems in peritoneal dialysis often result in discontinuation 
of this dialysis method. In this context, a relationship is supposed between recurrent 
peritonitis and access problems.9"11 Evidence for this hypothesis is also found in this 
survey, as ESIs predisposed to the development of peritonitis. For example, in 
patients with a history of ESI, 77% had one or more episodes of peritonitis, 
compared to 50% in those without a history of ESI. When ESI directly preceded 
peritonitis, 76% of the peritonitis episodes were caused by Staphylococcus aureus, 
indicating that the route of entry into the abdominal cavity is mainly extraluminal.12 
Consequently, prevention of ESI will reduce the number of peritonitis episodes and 
therefore improve the quality of life.6·13 
After the introduction of the Y-set, the number of peritonitis episodes 
declined drastically. Before the availability of the Y-set, the peritonitis rates were 
higher, ranging from 1.1 to 4.6 episodes/patient-year in the very beginning of 
peritoneal dialysis.1*"21 With the Y-set we found a peritonitis rate of 0.89 
episodes/patient-year, which is comparable with others,22 and even lower infection 
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rates of 0.44 - 0.56 episodes/patient-year have been described.23·24 The use of the 
Y-set resulted in a reduction of the number of peritonitis episodes per patient, which 
agrees with the findings of Piraino et af in a prospective randomized study. 
Furthermore, the number of patients without a peritonitis increased. 
In 1988, in our hospital antibiotic treatment of peritonitis was changed from 
a combination of cephalothin and gentamicin to cephradine. This decision was based 
on: 1) the toxicity of gentamicin (> 10% of the patients had severe, non-reversible 
vestíbulo- and/or ototoxicity), 2) the availability of orally administered antibiotics, 
and 3) the fact that intraperitoneal administration of antibiotics often includes 
hospitalization. The success rate of both antibiotic therapies was 83% and 60%, 
respectively. Compared to cephradine, the success rate of gentamicin/ cephalothin 
was significantly higher although morbidity and mortality of both antibiotic 
regiments were not different. On the other hand, the mean period of admission to 
the hospital was significantly lower for patients initially treated with cephradine 
(10.2 vs 5.6 days). Considering the failures of cephradine treatment, it appeared 
that the failure rate was very high when a gram-negative microorganism was 
responsible for the peritonitis episode. This was also the case with other first-
generation cephalosporins, such as cephalothin or cefadyl.25 The high failure rate 
can be explained when cephradine therapy was started in case the causative 
microorganism was not determined by Gram staining and appeared to be a gram-
negative microorganism in culture. 
Controversy exists in literature as to the use of cephradine or a first 
generation cephalosporin in general as initial treatment in CAPD peritonitis. For 
example, it was stated that a success rate of 66% with oral cephradine was an 
efficient way of treating peritonitis.19 A higher success rate of initial treatment with 
oral cephradine of 81 % was described but a 1-litre exchange every 30 minutes for 
48 hours after diagnosis was added to the drug therapy.26 Some even supposed that 
all first-generation cephalosporins are a rational choice of therapy while awaiting 
laboratory results.27 On the contrary, oral therapy with either cephradine or 
cephalexin was found unacceptable by others because of high failure rates.12,28 This 
was not caused by inadequate penetration into the peritoneal cavity but by their 
limited spectrum of activity.29 Anyhow, the antibiotic treatment should be adjusted 
to the microorganism found either by Gram stain and/or culture.30 Our present 
policy is to switch to vancomycin when the peritonitis does not adequately respond 
to the initial antibiotic treatment with cephradine or when a gram-negative 
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microorganism is found. In our opinion this is an adequate therapy regimen because 
the outcome in terms of morbidity, mortality and catheter removal is not different 
from treatment with a combination of gentamicin and cephalothin. Furthermore, 
initial treatment with vancomycin should be avoided because: 1) resistance to 
vancomycin should be prevented and 2) the drug is expensive. 
Apart from an adequate treatment regimen for peritonitis, prevention of 
peritonitis is preferable. As stated above, a strong correlation was found between 
the appearance of ESI and peritonitis. Several risk factors have been described for 
developing an ESI, such as poor hygiene, traction on the catheter and reduced 
immunologic defense.11 It is known that the design of the percutaneous access 
device can be of influence on the complication rate. For instance, Gokal et al stated 
that a new access device should be developed, giving special attention to the 
materials used, to avoid foreign body response as seen with the Dacron® cuffs of 
the Tenckhoff catheter. Furthermore, the design of the subcutaneous anchor should 
be able to eliminate motion at the exit-site and in this way reduce the number of 
ESIs.31 
Already various approaches have been tried to increase the stability of a 
percutaneous access device, thereby reducing stress at the interface between implant 
and skin. In most attempts, the cylindrical catheter was provided with a polymeric 
micro- or macroporous anchor. The hypothesis was that the porosity of the anchor 
would permit the ingrowth of connective tissue, hereby creating a strong mechanical 
connection with the surrounding subcutaneous tissue. Unfortunately, almost all 
designs ended in failure because of the inability to obtain well-vascularized 
connective tissue inside the porous materials used.3234 On the other hand, in 
laboratory animals a percutaneous access device provided with a titanium fibre mesh 
structure to anchor the device in the subcutaneous tissue showed promising 
results.353* Unfortunately, at the moment there still is no clinically applicable 
alternative for the peritoneal dialysis catheter. 
It can be stated that access problems are the Achilles' heel in peritoneal 
dialysis. Both exit-site infections and peritonitis are responsible for substantial 
morbidity and sometimes even mortality. Several improvements, such as the 
introduction of the Y-set, have reduced this morbidity. However, the presently used 
design of the access device is the main reason for the existing morbidity in 
peritoneal dialysis. Therefore more efforts should be undertaken to develop an 
access device, in which the design and the material used are critically reconsidered. 
47 
Access Related Problems 
2.5 References 
1 Alexander SR, Honda Μ· Continuous peritoneal dialysis for children· a decade of 
worldwide growth and development. Kidney Int 43. s65, 1993. 
2 Khanna R· Dialysis considerations for diabetic patients. Kidney Int 43: s58, 1993. 
3 Wizemann V, Timio M, Alpert MA, et al· Options in dialysis therapy, significance of 
cardiovascular findings. Kidney Int 43: s85, 1993 
4 Churchill DN: Comparative morbidity among haemodialysis and continuous ambulatory 
peritoneal dialysis patients Kidney Ini A3 sl6, 1993. 
5 Korbet SM Anaemia and erythropoietin in haemodialysis and continuous ambulatory 
peritoneal dialysis. Kidney Int 43: s i l l , 1993. 
6 Nolph KD' Access problems plague both peritoneal dialysis and haemodialysis. Kidney Int 
43: s81, 1993. 
7 Piraino B, Bernardini J, Sorkin Ml. The effect of the Y-set on catheter infection rates in 
С APD patients. Amer J Kidney Dis 16· 46, 1990 
8 Registratie Nierfuntievervanging Nederland Statistisch verslag 1992, Stichting Renine, 
Rotterdam, The Netherlands. 
9 Moncrief JW, Popovich RP' Continuous ambulatory peritoneal dialysis (CAPD), in Nolph 
KD (ed), Peritoneal Dialysis, 3rd ed Kluwer Academic Publishers, Dordrecht, The 
Netherlands, 1988 p. 152 
10 Piraino B, Bernardini J, Sorkin M: The influence of peritoneal catheter exit-site infections 
on peritonitis, tunnel infections, and catheter loss in patients on continuous ambulatory 
peritoneal dialysis. Amer J Kidney Dis 8: 436, 1986 
11 Scalamogna A, Castelnovo C, De Vecchi A, et al: Exit-site and tunnel infections in 
continuous ambulatory peritoneal dialysis patients. Amer J Kidney Dis 18: 674, 1991. 
12 Ludlam HA: Infectious consequences of continuous ambulatory peritoneal dialysis. J Hosp 
Infect 18: 341, 1991. 
13 Dryden MS, Ludlam HA, Wing AJ, et al Active intervention dramatically reduces CAPD-
associated infection. Adv Pent Dial 7: 125, 1991. 
14 Howard RL, Millspaugh J, Teitelbaum I: Adult and pediatric peritonitis rates in a home 
dialysis program, comparison of continuous ambulatory and continuous cycling peritoneal 
dialysis. Amer J Kidney Dis 16. 469, 1990. 
15 Gloor HJ, Nichols WK, Sorkin MI, et al' Peritoneal access and related complications in 
continuous ambulatory peritoneal dialysis. Amer J Med 74: 593, 1983. 
16 Smith WGJ, Tsakiris DJ, Junor BJR, et al: Peritonitis in continuous ambulatory peritoneal 
dialysis. Scot Med J 31: 85, 1986. 
17 Swartz RD: Chronic peritoneal dialysis: mechanical and infectious complications Nephron 
40- 29, 1985. 
18 Vogt К, Binswanger U, Buchmann Ρ, et al: Catheter-related complications during 
continuous ambulatory peritoneal dialysis (CAPD): a retrospective study on sixty-two 
double-cuff Tenckhoff catheters. Amer J Kidney Dis 10 47, 1987 
48 
Chapter 2 
19 Searle M, Raman GV Oral treatment of peritonitis complicating continuous ambulatory 
peritoneal dialysis Clin Nephrol 23 241, 1985 
20 Popovich RP, Moncnef JW, Nolph KD, et al Continuous ambulatory peritoneal dialysis 
Ann Intern Med 88 449, 1978 
21 Ariza M, Lopez M, Quesada Τ Complications of CAPD in children six years experience 
in Caracas, Venezuela Adv Peru Dial 7 269, 1991 
22 Bernardini J, Holley JL, Johnston JR, et al An analysis of ten-year trends in infections in 
adults on continuous ambulatory peritoneal dialysis (CAPD) Clin Nephroid 29, 1991 
23 Maiorca R, Cancanni GC, Brunon G, et al Morbidity and mortality of CAPD and 
haemodialysis Kidney Ini 43 s4, 1993 
24 Holley JL, Bernardini J, Piraino В Infecting organisms in continuous ambulatory peritoneal 
dialysis patients on the Y-set Amer J Kidney Dis 23 569, 1994 
25 Shah GM, Sabo A, Winer RL, et al Peritoneal leucocyte response to bacterial peritonitis 
in patients receiving peritoneal dialysis Int J Am/ Organs 13 44, 1990 
26 Knight KR, Polak A, Crump J, et al Laboratory diagnosis and oral treatment of CAPD 
peritonitis Lancet 8311 1301,1982 
27 Fenton Ρ Laboratory diagnosis of peritonitis in patients undergoing continuous ambulatory 
peritoneal dialysis J Clin Pathol 35 1181, 1982 
28 Tranaeus A, Heimburger O, Lindholm В Peritonitis in continuous ambulatory peritoneal 
dialysis (CAPD) diagnostic findings, therapeutic outcome and complications Peril Dial Ini 
9 179, 1989 
29 Bint AJ Pharmacokinetics of antibiotics in peritoneal dialysis J Anlimicrob Chemother 20 
626, 1987 
30 Saklayen MG CAPD peritonitis incidence, pathogens, diagnosis, and management Med 
Clin N Amer 74 997, 1990 
31 Gokal R, Ash SR, Helfnch GB, el al Peritoneal catheters and exit site practices toward 
optimum peritoneal access Pent Dial Ini 13 29, 1993 
32 Feldman DS, Von Recum AF Non epidermally induced failure modes of percutaneous 
devices Biomateriali 6 352, 1985 
33 Se h reu der s PD Salthouse TN, Von Recum AF Normal wound healing compared to 
healing within porous Dacron implants J Biomed Mater Res 22 121, 1988 
34 Yan JYJ, Cooke FW, Vaskelis PS, et al Titanium-coated Dacron* velour A study of 
interfacial connective tissue formation J Biomed Mater Res 23 171,1989 
35 Jansen JA, Van der Waerden JPCM, De Groot К Development of a new percutaneous 
access device for implantation in soft tissues J Biomed Mater Res 25 1535, 1991 
36 Jansen JA, Paquay YGCJ, Van der Waerden JPCM Tissue reaction to soft-tissue anchored 
percutaneous implants in rabbits J Biomed Mater Res 28 1047, 1994 
49 

CHAPTER 3 
Corrosion behaviour of 
metal fibre mesh structures 

3.0 CORROSION BEHAVIOUR OF METAL FIBRE MESH 
STRUCTURES 
3.1 Introduction 
Concerning the connective tissue response to subcutaneous implants, 
Campbell and von Recum1 demonstrated that surface texture of the implant was 
more important than the chemical composition. This finding was confirmed by a 
study2 in which we evaluated the connective tissue response to three different 
sintered fibre mesh materials: (1) titanium fibre mesh; (2) stainless steel (316L) 
fibre mesh; and (3) Fe-Cr-Al alloy fibre mesh. After 12 weeks of implant healing, 
all tested materials showed a good biocompatible behaviour. In addition, the results 
appeared to indicate a relation between flexibility of the used fibre meshes and 
tissue reaction. Consequently, an additional experiment3 was performed to test the 
hypothesis that the soft tissue response to fibre mesh materials can be influenced by 
changing the flexibility of these materials. For this study sintered stainless steel 
fibre web implants with varying flexibilities were used. This property was created 
by using different fibre diameters for the production of the meshes. The choice of 
stainless steel was based on the earlier observation that apparently the bulk 
composition of the mesh structure does not effect the surrounding tissue 
morphology. The implants were inserted subcutaneously into the dorsum of rabbits 
and left in situ for 16 weeks. It was found that especially mesh materials with a 
small fibre diameter (2-8 μπι) were lined by several layers of macrophages and 
giant cells. In addition, the majority of these mesh implants were filled with 
inflammatory cells. In contrast, mesh materials with a fibre diameter of 12 or 22 
μπι did evoke less or no inflammatory reaction. Inside the 22 μπι meshes even 
young fibroblasts and blood vessels were present. Two explanations were given for 
this observation. First, the flexibility of the originally used meshes (22 μπι) was 
already optimal. Second, the occurrence of shear displacements at the soft tissue 
implant interface, together with corrosion phenomena as a result of the increased 
surface area of small fibre diameter meshes, are responsible for a greater ion 
release. Consequently, the toxic properties of these ions elicit the tissue response. 
In light of the above mentioned findings, the purpose of this study is to 
compare the corrosion rates and the influence of shear stress on the corrosion rates 
of different stainless steel 316L fibre mesh structures under in vitro laboratory 
conditions. 
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3.2 Materials and methods 
3.2.1 Fibre mesh structures 
For this study three different sintered stainless steel and one titanium fibre 
mesh material were used. Based on earlier reports about its corrosion resistance,4 
the titanium mesh served as reference material. According to the information 
provided by the manufacturer the porous metallic fibre meshes were fabricated by 
interengaging and intertwining a multiplicity of metallic fibres. After compression 
the fibre structures were sintered to bond the fibres at their points of contact. All 
mesh materials used for the experiments had a volumetric porosity of 86% and a 
weight of 600 g/m2. The fibre diameters of the stainless steel were 4, 12 or 22 μπι, 
while the fibre diameter of the titanium mesh sheet was 50 μνη. 
Prior to the experiment, the surface composition of all types of mesh sheets 
was analyzed by energy dispersive x-ray analysis (EDS, Philips 525). The flexibility 
of the materials was determined as deflection per unit load in a three point bending 
test as performed with a thermal mechanical analyzer (Mettier TMA 40). With the 
same equipment also the thickness of the various mesh materials was measured. 
Furthermore, cross sections of the meshes perpendicular to the direction of the 
fibres were made and examined with reflected light microscopy. By using computer 
based image analysis (TCL-image) we measured the circumference in proportion 
to the surface area of the fibres, present in each cross section. The length of the 
circumference gives an indication of the potential contact surface of the different 
mesh materials. At least three specimens of each material were used for all the 
measurements. 
3.2.2 Corrosion testing method 
Shear stress occurring during subcutaneous maintenance can disrupt the 
oxide film present along the metallic mesh fibres and cause fretting corrosion at the 
points of contact. This will result in the release of metal ions. Therefore, to 
simulate the effect of in vivo movement, the various metal fibre structures were 
tested under static and dynamic conditions. For both experiments, test specimens 
of 8 χ 2 cm were used. The structure of the equipment as used for the dynamic 
testing is shown in figure 1. The fibre mesh, together with a rubber sheet is fixed 
on a cylindrical tube (diameter 45 mm, height 30 mm) and placed inside a 
cylindrical container (diameter 50 mm, height 65 mm). On top of the mesh a 
spherical structure is placed and, after addition of test fluid, the container is sealed 
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with a rubber sheet. The test specimens for the static experiments were placed in 
the same container as used for the dynamic conditions. 
Figure 1: The structure of the equipment for the dynamic testing 
of the fibre mesh structures. 
An apparatus, consisting of an ас-motor and low gear box, with an eccentric 
rotating axis-system was connected to a crank-shaft. A horizontally placed plate was 
fixed to the crank-shaft. In this way cyclic external stress on top of the test 
containers could be provided by sinusoid movement of the plate. The rotation 
velocity of the motor was 150 r.p.h. Cyclic external stress upon the upper rubber 
sheet will, through the sphere, provide stress on the fibre structure. Recovery of 
displacement was provided by the elastical properties of the rubber sheet at the 
lower side of the mesh until the consecutive moment of external stress appears. 
3.2.3 Corrosion test 
Test sample coupons of the various mesh materials were prepared. One 
hour prior to the experiments, the materials were cleaned by ultrasonic vibration in 
70% alcohol. Thereafter, they were rinsed with distilled water and airdried. 
After fixation of the test specimens, the static and dynamic fluid containers, 
as described above, were filled with 100 ml of medium. Three different incubation 
media were used: 
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1. 0.9% aqueous NaCl (solution of 9 g of extra pure sodium chloride 
powder in 1000 ml distilled water) 
2. buffered lactate solution (0.9% aqueous NaCl with 40 g/1 lactic 
acid, pH = 3) 
3. buffered lactate solution with 10% fetal calf serum (Gibco) 
All containers were covered with a rubber sheet to prevent evaporation and 
contamination. Subsequently, for the dynamic experiment the containers were fixed 
on a horizontal specimen holder and cyclic stress was applied during a period of 30 
days as described above. The temperature was kept constant at 37 'C ± 1 °C. The 
static experiment was performed for the same experimental time and under the same 
environmental conditions. The tests were performed on two specimens of each type 
of fibre mesh in all three media. 
After 30 days the fibre mesh structures were removed from the test media 
and divided in two parts. One part was directly airdried, the second part was rinsed 
with alcohol 70% to remove salt- and protein precipitation and airdried. 
Subsequently, the different specimens were prepared for scanning electron 
microscopy (SEM) and EDS. 
The different test fluids were subjected to atomic absorption 
spectrophotometry (Varían AAS 775, Australia) to determine the concentrations of 
elements in the solutions. The spectrophotometer was calibrated before use with 
calibration curve points chosen, depending on the expected range of the different 
element concentrations. 
3.3 Results 
3.3.1 Materials characterization 
Figure 2a and b are scanning electron micrographs of two 316L meshes, 
which show the surface aspects of the metal fibre structures. The SEM analysis 
revealed that the surface of the metal fibres with a diameter of 4 μηι had a rather 
smooth appearance. On the 22 μηι fibres shallow longitudinal grooves were 
observed. Examination of the titanium fibres showed the presence of irregular, 
rather profound, longitudinal grooves (figure 3). After testing, SEM showed no 
changes in surface morphology of the different fibre structures compared to the 
micrographs taken before. In Table 1 the mean pore size, flexibility, thickness and 
circumference per area of the different fibre meshes are listed. 
56 
. Chapter 3 
g
 "JÊ Ш 
0.1minl5.0kU 6.8ΘΕ2 З З / 1 9 3 1 6 L 8 4 
Figure 2: Scanning electron micrographs showing the surface aspects of the 
stainless steel 316L fibre structures: (a) 4 \un fibre and φ) 22 μ/η fibre. 
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Figure 3: Scanning electron micrograph of the titanium fibres. 
Table 1. Characteristics of the fibre mesh materials. 
Material 
316L/4 μπι 
316L/12 μπι 
316L/22 μπι 
Ti/50 μπι 
Mean 
pore size 
(¿im) 
14.82 
43.29 
43.68 
170.8 
Mean 
flexibility 
(μΝ) 
353 
1300 
673 
360 
Mean 
thickness 
(mm) 
0.54 
0.54 
0.53 
0.80 
Circumference 
per fibre area 
(μπι) 
0.81 
0.35 
0.19 
0.05 
Table 2 gives the surface composition of the received mesh materials, as 
determined by energy dispersive x-ray analysis. It appeared that the stainless steel 
316L mesh materials were composed of iron, chromium, nickel and molybdenum 
while the surface of the titanium mesh was mainly composed of titanium. Figure 
4 shows the EDS-spectrum of a stainless steel fibre mesh after the experiments were 
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performed; no significant difference were noticed in surface composition before and 
after testing. 
Table 2. Atom % of mesh materials found with EDS. 
Material 
Iron 
Chromium 
Nickel 
Molybdenum 
Titanium 
316L 
70.1% 
19.1% 
8.3% 
2.5% 
0% 
Titanium 
0% 
0% 
0% 
0% 
100% 
1J6L -J HU RCFTRFNIH 
Figure 4: The energy dispersive x-ray analysis of a stainless steel fibre mesh 
after the experiments were performed. 
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3.3.2 Atomic absorption spectrophotometry 
Figure 5 a, b and с show graphically the concentrations of respectively iron, 
chromium and nickel measured in the different media after testing the 316L mesh 
material. In none of the media, molybdenum could be detected. In the series of 
titanium experiments, no traces of titanium release could be found. 
( · ) IRON (b) CHROMIUM 
(c) NICKEL 
0 »% NtCI L a c t · ! · 
Α μπι stress + 
22 μπι stress < 
I 4 μπι stress · 
12 μπι stress + I * 12 μπι stress -
+ У . ι ; I 22 μπι stress 
0 9% NaCI Lactate 
Figure 5: The concentrations of respectively iron (a), chromium φ) and 
nickel (c) measured in the different media after testing 
the stainless steel 316L mesh material. 
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Considering the effect of different media, in 0.9% NaCl for all 316L 
materials no substantial release of ions was observed, both in the statical and 
dynamic situation. Further, there was a suggestion, that the release of corrosion 
products was reduced in buffered lactate with serum compared to the buffered 
lactate solely. Statistical analysis, using the Students t-test, after pooling the 
different ion concentrations, revealed a significant decrease in ion release 
(p< 0.001) for meshes incubated in serum supplemented lactate solutions. 
To determine the effect of mechanical stress on 316L corrosion, all data for 
the static and all data for the dynamic testing situation were added. The Students 
t-test for the comparison of the means revealed a significant increase in the 
concentration of corrosion products in the dynamic situation (p<0.01). 
To examine the effect of fibre diameter in the release of corrosion products, 
a one-way analysis of variance (ANOVA) and a multiple comparison procedure 
(Newman-Keuls) was applied using the data as given in figures 5 a, b and c. The 
analysis showed a significant difference (p<0.01) in ion release between the mesh 
materials made of fibres with a diameter of 4 μίτι compared to meshes with a 
diameter of 12 and 22 μτη. The existence of a relationship between the fibre 
diameter and the release of corrosion products was confirmed by performing a 
simple linear regression test. The computed correlation coefficient varied from -
0.6500 to -0.8189 for the fibre diameter using the data given in figure 5 a,b and с 
with the strongest correlation for the amount of iron release. If we take the 
measured circumference per area of the different stainless steel 316L meshes in 
concern the computed correlation coefficient, varying between 0.7643 and 0.9133, 
shows an even stronger association between the variables. 
3.4 Discussion 
The aim of this comparative study was to investigate the corrosion 
behaviour of stainless steel 316L fibre mesh structures under laboratory conditions. 
As this study showed, the 316L meshes fabricated of fibres with a small 
diameter released significantly more corrosion products compared to the meshes 
with a large fibre diameter. This phenomenon can be attributed to a larger surface 
area of the meshes, containing fibres with a small diameter.5 In addition, the 
outcome of this study can be related to the results we found in an in vivo 
experiment, where a correlation between the tissue behaviour and the fibre diameter 
of the various 316L stainless steel meshes was found.3 It has to be noted that this 
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is in contrast with Campbell and von Recum, who claim that the chemical 
composition of the implant is of minor importance compared to the surface 
geometry, as the tissue reaction is concerned.' Our experiment showed that, 
although the bulk material is the same in the various mesh materials, the amount 
of corrosion products surrounding the implant has markedly influenced the tissue 
behaviour. 
Furthermore, it appeared that the test medium is of influence on the 
corrosion rates. In contrast with 0.9% NaCl medium a substantial ion release was 
observed, both under statical and dynamic conditions, in lactate containing medium. 
This phenomenon implicates that other factors than shear stress alone, are 
responsible for the initiation of the corrosion process. The low pH of the lactate 
containing media could be the trigger of this process. Because a low pH is also 
found in tissue surrounding an implant during the early stages of wound healing,67 
the corrosion process can be easily initiated in vivo. As our results show, addition 
of serum to the lactate solution reduces the corrosion rates significantly. Generally, 
the presence of serum proteins elevates the corrosion rates, although some in vitro 
experiments showed a markedly reduction in fretting corrosion of stainless steel.8 
On the contrary, the titanium meshes seem not to be affected by the 
different test media because no titanium could be detected. This low ion release can 
explain why the tissue reaction to the meshes, placed subcutaneously, could be 
qualified as good.29 In addition, the biocompatible behaviour of titanium exists 
because a highly adherent and protective oxide film forms around the surface of the 
metal implant.41011 Whenever titanium ions are released, by for example wear or 
shear stress, the extremely high affinity for oxygen will automatically take care of 
the formation of electroneutral hydroxides and oxides. In contrast to our corrosion 
experiment, others described high levels of titanium in tissue surrounding titanium 
implants, but it also appeared that this had little effect on tissue morphology and did 
not produce any clinically symptoms.1213 Although it has to be emphasized that 
occasionally distant effects such as lymphadenopathy were reported in literature.14 
Other metals, like stainless steel or CoCrMo alloys, release corrosion products 
which are charged and not inert in tissue. This explains the tissue reaction we 
observed in the previous study,1 although the amount of release of corrosion 
products also seems to be important for the tissue reaction. 
In summary, the results of the present study show a correlation between the 
amount of corrosion products and the fibre diameter of the stainless steel mesh 
62 
Chapter 3 
materials. It confirms our hypothesis that, apart from for instance surface texture, 
the chemical properties of the implant material are still an important determinant 
in tissue behaviour. 
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4.0 TISSUE REACTION TO DACRON® VELOUR AND TITANIUM 
FIBRE MESH USED FOR ANCHORAGE OF PERCUTANEOUS 
DEVICES 
4.1 Introduction 
As reported earlier,12 peritoneal dialysis has some important advantages 
compared to more conventional dialysing methods, like haemodialysis. For 
example, peritoneal dialysis is more convenient to the patient, considering the 
positive social and medical implications of this method. Peritoneal dialysis is also 
relatively cheap and simple. 
The method of peritoneal dialysis is based on the capacity of the peritoneum 
to exchange fluid and metabolic products. Therefore, dialysis fluid has to be 
instilled in the abdominal cavity through a permanent percutaneous access device. 
Most of the currently used catheters for peritoneal dialysis consist of a silicone tube 
with porous polyethylene terephthalate (Dacron®) cuffs attached to it. Unfortunately, 
access related complications, such as exit-site infections, occur. A retrospective and 
prospective study, as performed in our hospital, showed that 35% of the standard 
catheters had to be removed because of infectious complications.2 In addition, a 
strong correlation was observed between the appearance of exit-site infections and 
recurrent peritonitis.23 
Though it is known that the design of the dialysis catheter is of influence 
on the incidence of complications, an ideal peritoneal catheter is still not available. 
Much research has already been performed to develop a percutaneous device that 
can be maintained functional for long periods.4"16 The purpose of these considerable 
research efforts was to obtain a tight skin seal in the percutaneous area which can 
prevent the downward migration of epidermis and the influx of bacteria. To achieve 
this, the devices were provided with a micro- or macroporous anchor, often made 
of Dacron® velour. Despite the disappointing results as described above, this 
material is still used for the currently available peritoneal dialysis catheters. 
Therefore, recently Gokal17 emphasized again the necessity of new improved access 
devices. This research should be focused on (1) the application of more 
biocompatible materials to avoid foreign body response, and (2) the design of the 
subcutaneous anchor to diminish motion at the exit-site and reduce the number of 
exit-site infections. 
During the last decennium in our laboratory research was directed toward 
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a better understanding of percutaneous implant failures and the development of 
more successful percutaneous devices.1822 These experiments have resulted in a 
percutaneous device provided with a subcutaneous flange made of a porous sintered 
titanium fibre mesh structure.23 Various animal experiments already showed the 
efficacy of our device. For example, it has been proven that: (1) ingrowth of 
connective tissue into the pores of the fibre mesh took place, (2) no, or only very 
limited, epidermal downgrowth was present after six months of implantation, and 
(3) no percutaneous exit-site infections occurred. However, no comparative studies 
were performed between the titanium fibre mesh and the Dacron® velour as used 
in the original Tenckhoff catheter. Consequently, the purpose of this study was to 
compare the differences in soft tissue reaction to Dacron® velour and titanium fibre 
mesh under the same experimental conditions. 
4.2 Material and methods 
4.2.1 Implant materials 
We used two different types of implants in the experiments. One of the. 
implants is shown in figure 1. This implant is a section of the commercially 
available Tenckhoff catheter (Quinton®, Seattle, USA). It consists of a silicone tube 
with a polyethylene terephthalate Dacron® cuff attached to it by means of Silastic 
medical Silicone A adhesive. The length of the silicone tube is 7 cm. To avoid 
ingrowth of tissue, both endings of the silicone tube are sealed with medical grade 
silicone glue. 
Figure 2 shows the other implant used. The device consists of two elements: 
(1) a flange-shaped component, and (2) a holding element connected to a silicone 
tube. The flange-shaped part is composed of a mesh sheet of commercially pure 
sintered titanium fibres. The mesh was fabricated by interengaging and intertwining 
a multiplicity of commercially pure titanium fibres. After compression, the fibre 
structures were sintered to bond the fibres at their points of contact. The fibre 
diameter was 50 μπι. The volumetric porosity was 86%, and the weight of the mesh 
sheet was 600 g/m2. The fibre mesh measured 3 cm in diameter and the length of 
the silicone tube was 5 cm. The holding element was composed of PCTFE 
(polychlortrifluoroethylene: a copolymer of ethylene and chlortrifluorethylene). To 
avoid tissue ingrowth, the holding element is closed with a small plug and the 
silicone tube is sealed with medical grade silicone glue. 
Before insertion the implants were sterilized in an autoclave. 
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Figure 1: Part of the commercially available Tenckhoff catheter. 
Both Dacron9 velour cuffs together with the silicone tube are visible. 
The arrows mark the area of the implant used for the experiment. 
Figure 2: The implant consists of a flange shaped titanium fibre mesh, 
a PCTFE holding element and a silicones tube. 
The small plug seals the holding element. 
69 
Dacron® versus titanium 
4.2.2 Implantation procedure 
Fourteen healthy, adult (2-3 years of age), female Dutch goats weighing 
about 60 kg were used in the experiments. In each goat, four implants were 
inserted, two on the left and two on the right side of the spinal column in the soft 
tissue of the abdominal wall. The implants were left in situ for four months. 
Surgery was performed under general anaesthesia, induced by intravenous 
injection of penthobarbital 25 mg/kg and atropine (0.5 mg per animal). After oro­
tracheal intubation, anaesthesia was maintained by 2-3% ethrane through a constant 
volume ventilator. To reduce perioperative infection risk, prophylactic antibiotic 
Albipen® was administered for three days starting 1 h postoperatively. 
For the insertion of the implants, the animal was immobilized and the 
region distal to the costal ridge was shaved, washed and disinfected with povidone-
iodine. A longitudinal incision was made parallel to the spinal column. Lateral to 
this incision a subcutaneous pocket was created by blunt dissection with scissors 
between the subcutaneous fat layer and the musculus obliquus abdominis externus. 
Centrally in the subcutaneous pocket, the muscle was cleft parallel to the muscle 
fibres over a distance of about 0.5 cm and a small tunnel was created by blunt 
dissection. Then, the silicone tube was inserted in this tunnel until either the 
titanium fibre mesh or the Dacron® cuff was situated on top of the muscle layer. 
Thereafter the wound was closed using resorbable vicryl 2-0 sutures. A total of 56 
implants were placed; 28 implants provided with the titanium fibre mesh and 28 
implants with the Dacron® velour cuff. 
To assure complete randomization, the position of the various implants into 
the back was based on a split plot design. Balancing was done by Latin Square to 
exclude experimental influences. 
4.2.3 Histologic evaluation techniques 
After four months, the animals were sacrificed using an overdose of 
Nembutal®. After killing the animals, the implants with their surrounding tissues 
were excised immediately. Following fixation in 10% buffered formalin solution, 
the specimens were dehydrated by alcohol series. Subsequently, the tissue 
specimens were trimmed to remove excess tissue and embedded in methyl 
methacrylate. After polymerization thin (10 μπι) histologic sections were prepared 
using a modified diamond-blade sawing microtome technique.24 The sections, 
containing the implants and the surrounding tissues attached to them, were stained 
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with methylene blue and basic fuchsin and examined by light microscopy. 
To assess the soft tissue response to the implants, both histological and 
histomorphometric evaluations were performed. The histological evaluation 
consisted of thorough description of the observed tissue reaction. For the 
histomorphometric evaluation: 
1) the mean distance between the individual fibres of either the Dacron® 
velour or the titanium mesh was measured. 
2) the fraction of either Dacron® or titanium fibres with associated foreign 
body giant cells was determined according to a method described by 
Schreuders et al.25 For this purpose, the histological sections were examined 
at a total magnification of χ 160 by light microscopy. In each section, the 
number of Dacron®/titanium fibres with associated foreign body giant cells 
was counted inside four different, randomly chosen squares, measuring 500 
χ 500 μΐη. Then, this number was divided by the total number of 
Dacron®/titanium fibres, as determined inside each square. 
3) the tissue response was quantified by counting the number of nuclei of 
macrophages and foreign body giant cells in the interstitial tissue. This was 
performed at the four random spots described above, only for this 
histomorphometric analysis we used a square measuring 225 χ 225 μπι. 
4) earlier evaluations of retrieved human Tenckhoff catheters, revealed that a 
large portion of the Dacron® velour cuffs was filled with silicone glue. To 
confirm this observation, we measured the portion of Dacron® velour 
available for tissue ingrowth and compared it to the part of Dacron® velour 
filled with silicone glue (figure 3). 
All histomorphometric procedures were performed in five representative 
sections of each implant and done blindly by two different operators. 
4.3 Results 
4.3.1 Descriptive light microscopic evaluation 
Dacron9 velour cuff: it appeared that the Dacron® cuff was partially filled 
with silicone glue. Further evaluation of the prepared sections revealed that the 
tissue response to the silicone tube and the Dacron® cuff was relatively uniform. 
The silicone tubes were surrounded by a thin to medium-thin fibrous tissue capsule 
measuring five to 15 layers of cells. The capsule was commonly free from inflam-
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Figure 3: The portion of Dacron® velour available for tissue ingrowth 
(A) compared to the part of Dacron® velour filled with silicone glue (B). 
In this figure 35% of the cuff is available for tissue ingrowth. 
Original magnification χ 12.5, bar 244 \tm. 
matory cells. Most of the Dacron® cuffs were surrounded by a tissue capsule 
containing five up to 25 layers of fibroblasts (figure 4). Close to the Dacron® fibres 
of the cuff, occasionally inflammatory cells were observed. Inside the velour cuff, 
almost all Dacron® fibres were surrounded by a sleeve of macrophages and foreign 
body giants cells (figure 5). Between the fibres the porosity was filled with 
immature fibrous connective tissue, but this was only the case where an appropriate 
distance between the individual Dacron® fibres was present. 
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Figure 4: The Dacron9 cuff is surrounded by a thin fibrous tissue capsule. Inside 
the porosity, strands of fibrous tissue are present where an appropriate distance 
between the individual fibres exists. Original magnification χ 25, bar 120 μηι. 
Figure 5: Almost all Dacron9 fibres (arrows) are surrounded by a 
sleeve of macrophages and foreign body giants cells. 
Original magnification χ 100, bar 30 \¡m. 
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Titanium fibre mesh: the tissue response to the fibre mesh provided implants was 
also relatively uniform. The silicone tube was again surrounded by five to 15 layers 
of fibroblasts while the polymer (PCTFE) holding element was lined by a medium-
thin fibrous tissue capsule measuring 10 to 25 layers of cells. The capsule was 
commonly free from inflammatory cells. Around the fibre mesh material we 
observed a thin to medium-thin capsule, containing 5 to 15 layers of fibroblasts 
(figure 6). This capsule was free from inflammatory cells. Inside the porosity of the 
titanium mesh, more mature collagenous connective tissue was found (figure 7). 
Occasionally, macrophages were present in the interstitium and whenever foreign 
body giant cells were noticed, they were mostly lying on one side of the fibres. 
4.3.2 Histomorphometric evaluation 
The mean distance between the individual fibres of the Dacron® velour was 
111.6 μπι. Still, it has to noted that the distance between the internal fibres was 
smaller compared to the peripheral part of the Dacron® cuff. Inside the titanium 
fibre meshes, the mean distance between the individual fibres was 170.8 μτα. 
Second, we determined the ratio of fibres associated with foreign body giant 
cells compared to the total number of fibres in the indicated areas. It appeared that 
inside the Dacron® velour 91% + 4% of the fibres was associated with foreign 
body giant cells compared to only 23% ± 12% inside the titanium fibre mesh 
structure. Statistical analysis of these data, using a nonparametric test according to 
Wilcoxon, revealed that significantly more fibres in the Dacron® velour were 
associated with foreign body giant cells compared to the titanium mesh (p < 
0.001). 
Furthermore, we estimated the number of inflammatory cells inside the 
porosity of either the Dacron® velour and the titanium fibre mesh by counting 
number of nuclei in the above described areas. Inside the Dacron® velour 83.57 + 
29.50 nuclei and inside the titanium fibre mesh 27.50 ± 11.78 nuclei were counted 
in each area. Statistical analysis of these data, using a non-parametric test according 
to Wilcoxon, showed that this difference was significant (p < 0.001). 
We also measured the part of the Dacron® velour available for tissue 
ingrowth. It appeared that the part of the cuff filled with silicone glue was 51 % ± 
17%. 
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Figure 6: The titanium fibre mesh is surrounded by a thin to medium-thin fibrous 
tissue capsule. Original magnification χ 10, bar 303 μ/η. 
Figure 7: Inside the porosity of the titanium mesh, more matured collagenous 
connective tissue was found. Original magnification χ 25, bar 120 μ/η. 
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4.4 Discussion 
The purpose of this study was to compare the differences in soft tissue 
reaction to Dacron® velour and titanium fibre mesh, both materials used to anchor 
a percutaneous device. 
The observed tissue reaction to the titanium fibre mesh was similar to our 
earlier experiments.1,2122 Inside the titanium mesh, the number of inflammatory cells 
and foreign body giant cells was significantly lower compared to the Dacron® 
velour. In addition, more mature collagenous connective tissue was observed. Two 
explanations can be given for this difference in tissue behaviour between Dacron® 
and titanium. First, it can be related to differences in surface energetic properties. 
It is known that, in contrast to titanium, Dacron® has a low surface tension. 
Biomaterials with low-energy surfaces are reported to be less biocompatible. 
Various in vitro and in vivo studies demonstrated the influence of this parameter on 
the foreign body host response.26"29 It also appeared that radio frequency glow 
discharge treatment of implants, for instance, increases the wettability of these 
materials, resulting in an improved fibroblast behaviour to the implant surface. A 
second explanation is based on the findings of Steinemann,30 who described that the 
biocompatible behaviour of titanium occurs because the corrosion products are at 
saturation in living tissue and electroneutral. Therefore an implant made of titanium 
will not effect a local tissue reaction. 
In contrast to the difference in tissue reaction inside the porosity of the 
implants, the capsule thickness seems not to be influenced by the kind of implant 
material. This is in agreement with the observations reported earlier that the 
thickness of the fibrous tissue capsule is the result of the wound healing response 
to the surgical trauma and has no relation with the chemical compatibility of the 
implant material.31"12 
According to Tenckhoff, the Dacron® cuff applied in dialysis catheters and 
situated in the subcutaneous area fulfils two functions: (1) promotion of fibrous 
tissue ingrowth for fixation of the catheter, and (2) prevention of bacterial migration 
along the cuff into the subcutaneous area.33 It is also known that the rate of 
epithelial migration alongside a percutaneous device appeared to be dependent on 
the degree of connective tissue maturity inside the porosity of the implant.34 
However, as our evaluation shows, because of the production process already one 
half of the Dacron® cuff is filled with silicone glue. Furthermore, the ingrowth of 
fibrous tissue is very limited. After four months implantation, the remainder of the 
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cuff is mainly filled with inflammatory tissue. Despite a sufficient distance between 
the velour fibres to allow ingrowth, only some strands of fibrous connective tissue 
are present between the Dacron® cuff fibres. These findings are confirmed by 
earlier studies to the tissue reaction of Dacron® implants.2"'' ^ *"38 Combination of these 
observations with our earlier histological evaluation of experimental titanium mesh 
percutaneous devices placed in rabbits22 can only lead to the conclusion that the 
limited fibrous tissue ingrowth into the Dacron® cuff has to be the reason for the 
observed high failure incidence of this kind of device. 
In summary, we assume that both designed functions of the Dacron® cuff, 
i.e. fixation and percutaneous passage seal will never be obtained in this material. 
As a consequence, exit-site infections and peritonitis will continue to be the major 
complications of peritoneal dialysis In contrast, the tissue reaction to the titanium 
fibre mesh is significantly better. Therefore, a percutaneous device equipped with 
this material should be able to diminish the complication rates. 
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5.0 TISSUE REACTION TO SOFT-TISSUE ANCHORED 
PERCUTANEOUS IMPLANTS IN RABBITS 
5.1 Introduction 
As has been demonstrated in various studies, the long-term success of 
percutaneous implants relies on the barrier function of the skin at the percutaneous 
exit-site.1"4 In previous reports,57 we described that reduction of the relative 
movement between implant and skin increased the chances of a successful 
percutaneous device. To obtain this required reduction of skin movability, implants 
were inserted into the tibial and onto the cranial bone of experimental animals. 
However, there are many clinical situations where percutaneous implants cannot be 
anchored in or on underlying skeletal bone. For example, continuous ambulatory 
peritoneal dialysis requires the location of the percutaneous catheter in the relatively 
mobile tissue of the abdominal wall. Moreover, these devices are fabricated almost 
entirely of highly flexible materials, like polydimethylsiloxane (Silastic® rubber) and 
Polyurethane, which increases the instability of these conduits. In the past, various 
approaches have been tried to overcome this problem. In most of the attempts, the 
cylindrical catheter was provided with a macroporous or microporous subcutaneous 
anchor. The hypothesis was that the porosity of the anchor would permit the 
ingrowth of connective tissue and the development of a strong mechanical 
connection with the surrounding subcutaneous tissue. Unfortunately, almost all 
designs ended in failure because of the inability to obtain well-vascularized 
connective tissue inside the used porous materials.8"11 In the few successful implants 
another dilemma occurred: tissue necrosis above the rim of the subcutaneous 
anchor, leading to extrusion and inevitable failure of the implant.12 
Nevertheless, despite all the failures, it was imperative that a solution be 
found for the safe long-lasting fixation of solely soft-tissue anchored percutaneous 
implants. Therefore, it appeared appropriate to investigate other materials and tech­
niques to increase the success rates. For example, Ducheyne et α/13·14 developed a 
flexible porous titanium fibre structure for application in orthopaedic surgery. Based 
on its reported good performance in bone tissue, we decided to use this material for 
the fabrication of percutaneous devices that can be placed in soft tissue.1316 The 
implants consisted of a subcutaneous and a percutaneous component. Further, for 
the insertion of these implants we used a two-stage surgical procedure. In the first 
surgical session only the subcutaneous implant part was placed. In a second session, 
83 
Percutaneous devices 
3 months later, the percutaneous part was inserted. The outcome of our experiments 
demonstrated that these titanium fibre mesh materials, in combination with the 
surgical technique, evoked minor adverse tissue response and prolonged the 
longevity of the percutaneous devices. However, despite these favourable results, 
it has to be noted that (1) the described results deal only with relatively short 
implantation periods and (2) a number of implants failed because of failures in the 
implant design. Consequently, it is the purpose of this study to evaluate improved 
titanium fibre mesh conduits for a longer time period. 
5.2 Material and methods 
5.2.1 Implant materials 
Figure 1 shows the percutaneous device as used in the experiments. The 
device consists of two elements: (1) a flange-shaped subcutaneous component, and 
(2) a percutaneous component. The subcutaneous part is composed of a mesh sheet 
of sintered titanium fibres. The fibre diameter is 50 μπι. The volumetric porosity 
of the fibre structure is 86% and the weight of the mesh sheet is 600 gr/m2. The 
subcutaneous part measured approximately 3 x 4 cm. Centrally disposed in the 
subcutaneous part is a rigid titanium holding element composed of a threaded hole 
with a diameter of 0.9 cm. By means of the screw thread the percutaneous part can 
be firmly and stably anchored in the subcutaneous part. When a subcutaneous part 
is implanted, the threaded hole is closed by means of an auxiliary screw to avoid 
ingrowth of tissue into this hole. The percutaneous part comprises a massive 
cylindrical structure with a diameter of 0.9 cm and is made of 
polytetrafluoroethylene (Teflon). The percutaneous part is provided with a screw 
thread corresponding to the screw thread in the subcutaneous part. 
5.2.2 Animals and surgical procedure 
Fifteen adult New Zealand White rabbits were used in this experiment. 
During surgery the rabbits were sedated by intramuscular injection of Hypnorm 
(Janssen Pharmaceutica, Goirle, The Netherlands). 
The implants were inserted into the dorsum of the rabbits. Before insertion 
the implants were sterilized in an autoclave. The surgical technique for placement 
of the implants consisted of two stages. During the first session the subcutaneous 
part of the implants was inserted. Before the installation of these implants, the back 
of the rabbits were shaved, depilated, washed, and disinfected with iodine on both 
84 
Chapter 5 
Figure 1: Percutaneous implant used in the experiments. 
sides of the spinal column. After local administration of lidocaine, a longitudinal 
incision approximately 4 cm in length was made through the full thickness of the 
skin, parallel to the spinal column. Subsequently, lateral to the incision a 
subcutaneous pocket was created by blunt dissection with scissors. The 
subcutaneous part of the implant was placed in this pocket. Finally, the wound was 
carefully closed. To achieve healing of the implants into the subcutaneous tissue, 
they were then left for a period of 3 months before the second stage was performed. 
At the second session, a small incision was made through the skin over the implant. 
After exposing the central hole in the holding element of the subcutaneous part of 
the implant, the auxiliary screw disposed in the holding element was removed. 
Subsequently, the percutaneous part of the implant was fixed in the healed 
subcutaneous component by means of the screw thread. The last step was closure 
of the incision with one suture. 
All rabbits were inspected weekly, and during these inspections the 
percutaneous implantation sites were carefully cleaned. 
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5.2.3 Histologic procedure and evaluation methods 
Two and 6 months after the second surgical session the rabbits were 
sacrificed by injecting Nembutal peritoneally. Three rabbits were killed after 2 
months, and 10 rabbits 6 months after surgery. After killing the animals, the 
implants with their surrounding tissues were excised immediately and fixed in 10% 
buffered formalin. Subsequently, the tissue specimens were embedded in methyl 
methacrylate. After polymerization undecalcified thin (10 μίτι) histologic sections 
were prepared using a modified diamond-blade sawing microtome technique.17 
Several sections were taken of each implant on both sides of the percutaneous area. 
The sections containing the implants as well as the surrounding tissues attached to 
them were stained with methylene blue and basic fuchsin and investigated by light 
microscopy. 
epidermal downgrowth 
teflon / 
percutaneous part / 
Figure 2: Schematic drawing of the percutaneous implant showing 
the epidermal downgrowth measurement. 
To assess the soft tissue response to the implants, histologic and 
histomorphometric evaluations were performed. For the histologic evaluation the 
sections were examined in the (1) presence of an epithelial attachment, (2) direction 
of the connective tissue fibres, and (3) presence of a subepithelial inflammatory 
reaction. For the histomorphometry we measured the epidermal downgrowth (figure 
2) and we used a histologic grading scale, as shown in table 1, in which the 
histologic characteristics of the capsule surrounding the subcutaneous titanium mesh 
and the tissue inside the interstices of the mesh were evaluated by assigning scoring 
points. This evaluation method has been described extensively in earlier papers.1819 
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Table 1. Histologic grading scale for soft-tissue implants. 
capsule 
quantitatively 
capsule 
qualitatively 
interslitium 
qualitatively 
Response 
thickness rating 
1-4 fibroblasts 
5-9 fibroblasts 
10-30 fibroblasts 
> 30 fibroblasts 
Not applicable 
capsule tissue is fibrous, mature, not dense, resembling con-
nective or fat tissue in the non-injured regions 
capsule tissue is fibrous but immature, showing fibroblasts and 
little collagen 
capsule tissue is granulous and dense, containing both fibroblasts 
and many inflammatory cells 
capsule consists of masses of inflammatory cells with little or no 
signs of connective tissue organization 
cannot be evaluated because of infection or other factors not 
necessarily related to the material 
tissue in interslitium is fibrous, mature, not dense, resembling 
connective or fat tissue in the non-injured regions 
tissue in interstitiuin shows blood vessels and young fibroblasts 
invading the spaces, few macrophages may be present 
tissue in interstilium shows giant cells and other inflammatory 
cells in abundance but connective tissue components in between 
tissue in interstitium is dense and exclusively of inflammatory 
type 
implant cannot be evaluated because of problems that may not 
only be related to the material to be tested 
Score 
4 
3 
2 
1 
0 
4 
3 
2 
1 
0 
4 
3 
2 
1 
0 
In summary, the evaluation of the surrounding capsule was semiquantitative and 
semiqualitative, whereas the evaluation of the interstitial tissue was only 
semiqualitative. The semiquantitative classification consisted of a capsule 
measurement on basis of the observed number of fibroblasts. The semiqualitative 
rating of the capsule and interstitium consisted of numerically rating the tissue 
morphology (fibrous tissue, maturity, presence of connective tissue or fat tissue) 
and cellularity (presence of fibroblasts, macrophages, giant cells, and other 
inflammatory cells). 
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5.3 Results 
5.3.1 Macroscopic clinical findings 
The clinical results of the percutaneous implants in the rabbits are outlined 
in table 2. Of the 15 rabbits, two died because of pneumonia 1 month after insertion 
of the subcutaneous component of the percutaneous device. The rest of the 
experimental animals appeared to be in good health throughout the test periods. As 
assessed during the second surgical session, all subcutaneous titanium mesh implants 
showed good healing with the surrounding soft tissues. The rigid titanium holding 
element was always surrounded by a thin fibrous tissue capsule. 
Table 2. Survey of Clinical Findings 
Implants 
2 months 
(n = 5) 
6 months 
(n = 10) 
Inflammatory 
Reaction 
-
-
Skin 
Retraction 
-
1 
Implant 
Failure 
-
1 
Preliminary 
Death 
2 
-
At the end of the experimental periods, it was found that all 2 month 
implants were successful. Of the 6-month implants, one failed because the fibre web 
tore at the junction of fibre mesh-holding element. This failure occurred after an 
implantation time of 3 months. The successful 2- and 6-month implants displayed 
undisturbed wound healing without clinical evidence of an adverse skin reaction 
(figure 3). In only one 6-month implant, the skin was slightly retracted from the 
percutaneous element. 
5.3.2 Microscopic and histomorphometric findings 
Histologic analysis of the percutaneous devices confirmed the clinical 
findings. The sections of the 2- and 6-month implants demonstrated no downgrowth 
or a limited downgrowth of the pidermis, and a sinus tract was formed between 
the migrating epidermis and the percutaneous implant surface (figure 4). The sinus 
was filled with keratin. No inflammatory reaction was observed in the dermal 
connective tissue. In all specimens a thin fibrous capsule was formed around the 
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Figure 3: Clinical appearance of a successful percutaneous implant, showing no 
adverse tissue reaction 6 months after insertion. 
Figure 4: The percutaneous passage of a successful implant, 6 months 
postoperatively. The light micrographs illustrate that only a limited sinus (arrow) 
is formed between the epithelium and implant surface. (A) original magnification 
χ 16, bar 187 μ/η, (В) original magnification χ 40, bar 76 μm. 
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rigid holding part. The connective tissue fibres were arranged parallel to the 
titanium surface (figure 5). 
Examination of the subcutaneous tissue response to the titanium fibre sheets 
showed that the tissue response was relatively uniform. All mesh implants were 
surrounded by a thin fibrous tissue capsule. The capsule contained fibroblasts and 
collagen and was commonly free from inflammatory cells (figure 6). Inside the fibre 
web structure the porosity was filled with blood vessels and connective tissue. Only 
occasionally, scattered foci of macrophage or lymphocyte accumulations were 
observed. These macrophages were always concentrated at one side of the titanium 
fibres (figure 7). Several implants showed a fatty tissue ingrowth. There was no 
difference in tissue reaction between the 2- and 6-month percutaneous devices. 
The histomorphometric results are given in table 3. The following 
observations were made: 
1. Epithelial attachment formation occurred with all percutaneous devices 
independent of the degree of epidermal migration. 
2. No epidermal migration was seen at 2 months after implantation. 
3. Around four of the 6-months implants the epidermis showed no sign of 
migration. In the rest of the 6-month implants, the migration of the 
epidermis had extended no further than about one quarter of the titanium 
holding element (figure 8). Only in rabbit 280 did the epidermis migrate 
downwards over a considerable distance, which also resulted in clinical 
exposure of the holding element (figure 9). 
4. There was no subepithelial inflammatory reaction in any cases. 
5. The direction of the connective tissue fibres in the percutaneous area was 
always parallel to the implant surface. 
6. All subcutaneous titanium fibre meshes were surrounded by a thin, mature 
connective tissue capsule. 
7. In almost all cases, the titanium fibre mesh was filled with immature 
connective tissue; only in rabbit 280 was a mild inflammatory reaction seen 
inside the fibre mesh (figure 10). 
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Figure 5: Histologic section showing the fibrous tissue capsule surrounding the 
titanium holding plate, original magnification χ 25, bar 120 y¡m. 
Figure 6: Light micrograph showing the thin fibrous capsule, approximately six 
cell layers thick, surrounding the subcutaneous fibre mesh, original 
magnification χ 32, bar 94 \¡m. 
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Figure 7: Light micrograph of the subcutaneous mesh implant at 6 months: 
(A)The interstitium of the titanium fibre mesh is filled with blood vessels and 
connective tissue, original magnification χ 40, bar 76 \tm. 
(B)Present macrophages were always concentrated at one side of the fibres, 
original magnification χ 160, bar 19 urn. 
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Figure 8: Light micrograph of a six month percutaneous implant with maximal 
sinus formation of about one quarter of the titanium holding plate (arrow), 
original magnification χ 25, bar 120 μ/η. 
Figure 9: Histological section of a percutaneous device with clinical sign of skin 
retraction (rabbit 280). The epidermis had migrated downwards almost 
completely over the titanium holding element. The connective tissue in the 
percutaneous area is free of an inflammatory reaction, 
original magnification χ 10, bar 303 μ/π. 
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Figure 10: Light micrographs of the subcutaneous fibre mesh of rabbit 280. 
There is some local accumulation of macrophages inside the mesh implant. 
(A)original magnification χ 25, bar 120 μ/η. 
(B)original magnification χ 40, bar 76μΜ. 
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5.4 Discussion 
Supported by the observation that reduction of the relative movement 
between implant and skin increases the chances of a successful percutaneous device, 
we developed a new technique for the stabilization of percutaneous devices located 
in soft tissues. This method is based on the use of sintered titanium fibre-web 
material for the anchoring the percutaneous implant in the hypodermal area. 
In the present study, we demonstrated again that (1) this design favours the 
longevity of percutaneous devices inserted in subdermal tissue and (2) titanium 
mesh evokes a minor adverse reaction of the surrounding tissue. The successful 
healing event was associated with ingrowth into the mesh apertures of connective 
tissue, specifically fibroblasts, collagen fibrils, and blood vessels. Occasionally, a 
fatty tissue ingrowth was observed into the fibre mesh. However, this fat tissue did 
not influence the overall tissue response to the implants. This last observation does 
not corroborate with the findings of Picha et aP° who compared the soft tissue 
response between natural-Y polyurethane foam and smooth silicone. He observed 
that the presence of fat tissue within the foam interstices was associated with a 
decrease in the thickness of the surrounding fibrous tissue capsule. Although it is 
difficult to give an explanation, a possible reason for this influence of fatty tissue 
on the capsule configuration may be the use of a different experimental animal 
species, rat versus rabbit.21 
Furthermore, below the point where the epidermal migration arrested, the 
titanium holding element was surrounded by an arranged fibrous capsule consisting 
of fibre bundles running parallel to the implant surface. Because it is supposed that 
for the formation of a stable skin attachment, firmly attached perpendicularly 
arranged connective tissue fibres are required,22·23 the question of whether the 
epidermal downgrowth will proceed over time arises. Consequently, there is a 
definite need for long-term (2-3 years) follow-up experiments. Also, the conse-
quences of the collagen fibre orientation for long-term clinical results in dental 
implants are still points of discussion.24,25 However, a major problem with long 
lasting implant studies is that they cannot possibly be performed in small animals, 
like rabbits. This problem can only be overcome by using larger animal species, 
such as goats or dogs. 
The application of the two-stage surgical technique for the installation of the 
implants was based on experiences with bone-anchored percutaneous devices.2*·27 
During the healing interval, the surgically traumatized tissue should heal, resulting 
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in a complete incorporation of the implants. Because of this healing process, 
ingrowth and infection of the soft tissues will be prevented. To what extent this 
two-stage implantation has improved the success of our implant configuration is 
difficult to determine. On the other hand, it must also be admitted that for conduit 
systems, such as used for continuous ambulatory peritoneal dialysis, there is a need 
for one-stage access devices.28 In this context, in rabbit 280, in addition to the skin 
retraction, a mild inflammatory reaction also was observed inside the subcutaneous 
fibre mesh. The question arises whether this inflammatory response is caused by the 
epidermal downgrowth or whether this inflammatory process is a sign of incomplete 
subcutaneous healing, which in turn resulted in epidermal migration. Therefore, 
further investigations have to be performed to determine the influence of the 
surgical technique on the success rate of fibre mesh percutaneous implants. 
In conclusion, these experiments have demonstrated that stabilization of the 
percutaneous device in the hypodermal area using sintered titanium fibre mesh 
structure favours the longevity of percutaneous devices implanted in soft tissues. 
Considering this observation, more studies have to be performed to fully understand 
the clinical perspectives of this percutaneous implant design. 
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CHAPTER 6 
A one-stage versus a two-
stage surgical technique 

6.0 A ONE-STAGE VERSUS A TWO-STAGE SURGICAL TECHNIQUE 
6.1 Introduction 
Peritonea] dialysis has some important advantages above haemodialysis.1"5 
Briefly, the positive social and medical implications of peritoneal dialysis are more 
convenient to the patient. In addition, this method is relatively cheap and simple. 
Most patients can exchange the dialysis fluid, present in the abdominal cavity, at 
home without professional assistance. The percutaneous catheter used for peritoneal 
dialysis is located in the soft tissue of the abdominal wall and generally consists of 
a silicone tube with porous polyethylene terephthalate (Dacron®) cuffs attached to 
it. The purpose of the subcutaneous cuff is to obtain a tight skin seal in the 
percutaneous area, hereby preventing marsupialization and influx of bacteria.6 
Despite this provision, access related complications, like exit-site infections, occur. 
For instance, a retrospective and prospective study in our hospital showed that 35% 
of the peritoneal dialysis catheters had to be removed because of an infectious 
complication.7 Furthermore, the occurrence of peritonitis is correlated with these 
exit-site infections.7"9 
To prevent catheter-related infections, modifications in the catheter design 
have been made. For instance, Daly created a catheter entirely made of medical 
grade polyurethane.10 In addition, it was provided with a subcutaneous flange and 
a porous cuff placed at the peritoneal entry site. However, at clinical testing the 
main problem of the access device consisted of leakage of the dialysis fluid at the 
exit-site probably because of lack of connective tissue ingrowth in both the flange 
and cuff.11 Also the surgical technique for placement of the catheters was changed. 
For example, Moncrief et al used, analog with the installation of bone anchored 
percutaneous devices as applied in dental and maxillofacial surgery,1213 a so-called 
two-stage procedure.14 In the first surgical session they implanted modified 
Tenckhoff catheters using the standard technique, except for that the percutaneous 
part of the catheter was buried subcutaneously. After 3-5 weeks, to allow tissue 
healing, the percutaneous part of the catheter was exteriorized. They found that the 
peritonitis rate in patients on peritoneal dialysis decreased significantly without a 
reduction of the number of exit-site infections. In contrast to these results, Alvaro 
et al, using the same surgical technique and catheter, found a reduction of the exit-
site infection rate without a significant decrease in the peritonitis rate.15 
Considering the above mentioned, we also know that reduction of the 
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relative movement between implant and skin increases the life-time of a 
percutaneous access device.16"" This reduction of the movability can also be 
obtained by stabilisation of the interface between the tissue and implant. Combining 
all available knowledge with the currently obtained results, we decided to provide 
the peritoneal catheter with a subcutaneous flange made of porous sintered titanium 
fibre mesh. Further we used a two-stage surgical technique for placement of the 
devices. Animal experiments already showed the efficacy of our device in 
combination with the surgical procedure.20 For example, it has been proven that: 
(1) ingrowth of connective tissue into the pores of the fibre mesh took place without 
the extensive inflammatory response as found inside Dacron® velour, (2) no, or 
only very limited, epidermal downgrowth was present after six months of 
implantation, and (3) no percutaneous exit-site infections occurred. 
However, most clinicians prefer a one-stage surgical implant. Therefore, 
the purpose of this study was to investigate whether there is a difference in tissue 
reaction between the one-stage and two-stage percutaneous device provided with the 
titanium fibre mesh structure. 
6.2 Material and methods 
6.2.1 Implants 
We used two different types of implants in the experiments. Figure 1 shows 
a graphical cross-section of the so-called one-stage percutaneous device as used in 
the experiments. The device consists of two elements: (1) a flange-shaped 
subcutaneous component, and (2) a percutaneous component. The subcutaneous part 
is composed of a mesh sheet of sintered titanium fibers (Bekaert Fibre 
Technologies, Zwevegem, Belgium). The fibre diameter is 50 μπι. The volumetric 
porosity of the fibre structure is 86%, the weight of the mesh sheet is 600 gr/m2, 
the measured flexibility of the mesh was 360 + 18 μΝ and the thickness is 0.80 
mm. The subcutaneous part measured approximately 3 cm in diameter. Centrally 
disposed in the subcutaneous part is a rigid polymer percutaneous element 
composed of PCTFE (polychlortrifluoroethylene: a copolymer of ethylene and 
chlortrifluoroethylene), a material also used to manufacture heart valve implants and 
culture dishes. A silicone tube of 3 cm in length is attached to the percutaneous 
element. 
Figure 2 shows the so-called two-stage percutaneous device. In contrast to 
the one-stage implant, in this design the percutaneous element consists of two parts. 
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epidermal downgrowth 
percutaneous element 
Figure 1: Graphical cross-section of the one-stage percutaneous implant 
used in the experiment. The sulcus width and epidermal downgrowth 
are marked as is used in the histomorphometric evaluation. 
Figure 2: The two-stage percutaneous implant used in the experiment. 
The screw (I) is inserted in the holding element (2) during the first 
surgical procedure to avoid tissue ingrowth and replaced by 
the percutaneous part (3) at the second surgical session. 
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By means of a screw thread the percutaneous part can be firmly anchored to a 
holding element fixed in the centre of the subcutaneous component. When during 
the first surgical stage only the subcutaneous part is implanted, the threaded hole 
in the holding element is closed by means of an auxiliary screw to avoid ingrowth 
of tissue into this hole. 
6.2.2 Animals and surgical procedure 
Twelve healthy, adult (2-3 years of age), female Saane goats weighing about 
60 kg were used in the experiments. In each goat, two different types of implants 
were inserted, one on the left and one on the right side of the spinal column in the 
soft tissue of the abdominal wall. Before surgery, the implants were sterilized in an 
autoclave. Surgery was performed under local anaesthesia with lidocaine. Before 
the insertion of the implant, the animal was immobilized and the region distal to the 
costal ridge was shaved, washed and disinfected with povidone-iodine. 
During the first session of the two-stage surgical procedure, only the 
subcutaneous part of the two-stage percutaneous device was inserted. A longitudinal 
incision, approximately 4 cm in length, was made through the full thickness of the 
skin, parallel to the spinal column. Subsequently, lateral to the incision a 
subcutaneous pocket was created by blunt dissection with scissors. The 
subcutaneous part of the implant was placed in this pocket. Finally, the wound was 
carefully closed. To achieve healing of the implants into the subcutaneous tissue, 
they were left for a period of 6 weeks before the second stage surgical procedure 
was performed. At the second session, after lidocaine infiltration of the skin, a 
small incision was made through the skin over the implant. After exposing the 
central hole in the holding element of the subcutaneous part of the implant, the 
auxiliary screw disposed in the holding element was removed. Subsequently, the 
percutaneous part of the implant was fixed in the subcutaneous component by means 
of the screw thread. The last step was closure of the incision with one straight 
suture. 
Furthermore, during this surgical session the one-stage percutaneous implant 
was inserted on the contra-lateral side of the goat. For the implantation of this 
device, the same surgical procedure was used as described above with the exception 
that the percutaneous part of the implant directly protruded through the skin without 
intervening healing period. 
To reduce perioperative infection risk, prophylactic antibiotic Ampicillin 
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500 mg was administered intramuscular for three days starting one hour 
postoperatively. The implants were left in situ for four months after the last surgical 
procedure without any coverage of the exit-sites. During this period the group of 
animals were stabled in a separate room. Furthermore, the heads of the goats were 
fixed between two vertical bars to prevent the animals from manipulating the 
percutaneous devices (figure 3). Daily care was provided by the technicians without 
manipulating the implants. In addition, the goats were inspected once every two 
weeks, and during these inspections the exit-sites of the percutaneous devices were 
carefully cleaned and photographed. 
Figure 3: After the second surgical session the heads of the goats were fixed 
between two vertical bars to prevent manipulation of the percutaneous devices. 
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6.2.3 Histologic procedure and evaluation methods 
Four months after the surgical session during which the one-stage implants 
and the percutaneous part of the two-stage implants were placed, the implants were 
excised under local anaesthesia and the wounds were carefully closed. The implants 
with their surrounding tissues and overlying skin were fixed in 10% buffered 
formalin solution followed by dehydration with alcohol series. Subsequently, the 
tissue specimens were trimmed to remove excess tissue and embedded in methyl-
methacrylate. After polymerization of the methyl-methacrylate thin (10 μπι) 
histologic sections were prepared using a modified diamond-blade sawing 
microtome technique.21,22 At least five sections were taken of each implant on both 
sides of the percutaneous area and were made in same direction as the longitudinal 
axis of the percutaneous component. The sections containing the implants as well 
as the surrounding tissues attached to them, were stained with methylene blue and 
basic fuchsin and investigated by light microscopy. 
To assess the soft tissue response to the implants, both histologic and 
histomorphometric evaluations were performed. The histologic evaluation consisted 
of thorough description of the observed tissue response. For the histomorphometric 
evaluation: 
1) the epidermal downgrowth ( = the distance of epidermal migration 
alongside the implant) and the sulcus width ( = the distance between the 
percutaneous component of the device and the skin) was measured, as 
marked in figure 1. 
2) a histologic grading scale was used, as shown in table I. On basis of this 
scale, the histologic characteristics of the capsule surrounding the 
subcutaneous titanium mesh and the tissue inside the interstices of the mesh 
were evaluated by assigning scoring points. This evaluation method has 
been described extensively in earlier papers.23·24 In summary, the evaluation 
of the surrounding capsule was semiquantitative and semiqualitative, 
whereas the evaluation of the interstitial tissue was only semiqualitative. 
The semiquantitative classification consisted of a capsule measurement on 
basis of the observed number of fibroblasts. The semiqualitative rating of 
the capsule and interstitium consisted of numerically rating the tissue 
morphology (fibrous tissue, maturity, presence of connective tissue or fat 
tissue) and cellularity (presence of fibroblasts, macrophages, giant cells, and 
other inflammatory cells). 
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Table 1. Histologic grading scale for soft-tissue implants. 
capsule 
quantitatively 
capsule 
qualitatively 
interstitium 
qualitatively 
Response 
thickness rating 
1-4 fibroblasts 
5 9 fibroblasts 
10-30 fibroblasts 
> 30 fibroblasts 
Not applicable 
capsule tissue is fibrous, mature, not dense, resembling con 
nective or fat tissue in the non-injured regions 
capsule tissue is fibrous but immature, showing fibroblasts and 
little collagen 
capsule tissue is granulous and dense, containing both fibroblasts 
and many inflammatory cells 
capsule consists of masses of inflammatory cells with little or no 
signs of connective tissue organization 
cannot be evaluated because of infection or other factors not 
necessarily related to the material 
tissue in interstitium is fibrous, mature, not dense, resembling 
connective or fat tissue in the non-injured regions 
tissue in interstitium shows blood vessels and young fibroblasts 
invading the spaces, few macrophages may be present 
tissue in interstitium shows giant cells and other inflammatory 
cells in abundance but connective tissue components in between 
tissue in interstitium is dense and exclusively of inflammatory 
type 
implant cannot be evaluated because of problems that may not 
only be related to the material to be tested 
Score 
4 
3 
2 
1 
0 
4 
3 
2 
1 
0 
4 
3 
2 
1 
0 
3) the tissue response was quantified by counting the number of blood vessels, 
foreign body giant cells and inflammatory cells in the interstitial tissue. For 
this purpose, the microscopic images were projected with a total 
magnification of χ 400 on a colour monitor using a colour camera attached 
to the light microscope. Subsequently, the occurrence of blood vessels and 
foreign body giant cells was calculated in a representative part of the 
titanium fibre mesh. The occurrence of inflammatory cells was estimated 
by superimposing a net ruling, consisting of 176 smaller squares (1.5 χ 1.5 
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cm) on the colour monitor. Then, the number of inflammatory cells in five 
randomly marked squares per field was counted. 
All histomorphometric procedures were performed in one representative 
section of each implant and done blindly by two different operators. 
6.3 Results 
6.3.1 Macroscopic findings 
Of the 12 goats, one animal was excluded from the experiment because of 
a persistent scabies infection, not responding to antiparasitic drugs. This infection 
was not related to the percutaneous implants. The remainder of the experimental 
animals appeared to be in good health throughout the test periods. At the second 
surgical session, it was observed that all two-stage subcutaneous implants showed 
good healing with the surrounding soft tissue The PCTFE holding element was 
surrounded by a thin fibrous tissue capsule. 
Table 2. Survey of histomorphometric findings (mean ± SD). 
Maintained (no) 
Lost (no) 
Epidermal downgrowth (mm) 
Sulcus width (mm) 
Capsule thickness (sp") 
Capsule quality (sp") 
Inlerstitium quality (sp") 
Bloodvessels (no) 
Foreign Body Giant cells (no) 
Inflammatory cells (no) 
one-stage percutaneous 
device 
η = 11 
7 
4 
3 29 + 1 75 
0 79 + 0 89 
4 14 + 0 69 
3 71 ± 0 95 
3 0 0 + 0 0 0 
4 54 + 3 23 
2 9 2 + 1 04 
4 46 + 2 15 
two-stage percutaneous 
device 
η = 11 
11 
0 
3 40 + 1 75 
0 80 + 0 76 
4 20 + 0 92 
4 00 + 1 05 
3 0 0 + 0 0 0 
5 64 + 3 30 
1 71 + 1 14 
3 79 + 1 63 
" sp = scoring points as outlined in table I. 
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Despite the precautionary housing of the animals, 4 one-stage implants 
disappeared during the period of investigation (table 2). One implant disappeared 
after 1 month and three implants after 3 months. Before these implants disappeared 
retraction of the skin was already observed. The lost implants could not be found. 
Probably they were removed while cleaning the stable. All two-stage implants were 
in situ throughout the testperiod. Statistical analysis, using Chi square analysis, 
showed that this difference in clinical success between the one- and two-stage 
implants was significant (p<0.05). All successful one- and two-stage implants 
displayed undisturbed wound healing without clinical evidence of an adverse skin 
reaction (figure 4). In four of the seven one-stage implants left, the skin was 
slightly retracted from the percutaneous element (figure 5). This was also the case 
with five of the eleven two-stage percutaneous devices. Statistical testing showed 
no significant difference in the occurrence of this phenomenon between both 
groups. 
Figure 4: A macroscopic image of a successful percutaneous device 
after four months implantation. 
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Figure 5: Skin retraction (arrow) around the percutaneous element, 
four months after the second surgical session. 
6.3.2 Descriptive light microscopic evaluation 
Histologic analysis of the percutaneous devices showed that the epidermal 
downgrowth never extended further than the width of the PCTFE holding element. 
Between the migrating epidermis and the percutaneous surface, the sinus tract was 
filled with keratin (figure 6a and 6b). At the bottom of the sinus, the epithelium 
mostly appeared to form a junction with the surface of the holding element (figure 
7). In the dermal connective tissue, no inflammatory reaction was observed. 
Further, the rigid holding element was surrounded by a thin fibrous tissue capsule. 
In one one-stage and two two-stage implants no downgrowth was observed at all. 
The titanium fibre meshes were either surrounded by a thin fibrous tissue 
capsule (figure 8) or no tissue capsule was observed. The capsule contained 
fibroblasts and collagen and was commonly free from inflammatory cells. Inside the 
porosity, the fibre web structure was filled with connective tissue and bloodvessels 
(figure 9). Occasionally, scattered foci of macrophages or foreign body giant cells 
were observed. They were mostly lying on one side of the titanium fibers. 
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Figure 6: (a) A histological cross-section of a two-stage percutaneous implant 
without clinical evidence of skin retraction. The percutaneous part of the device 
and the skin is shown. In addition, part of the screw thread of the holding 
element is visible. Epidermal downgrowth proceeded until the edge of the 
holding element. The sinus is filled with keratin (arrow). 
(b) The skin retraction surrounding a one-stage implant was already evident 
during clinical inspection. Again only the percutaneous part 
of the implant and the skin is visible. 
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Figure 7: At the bottom of the sinus between skin and percutaneous part of the 
implant, the epithelium appears to form a stable junction with the surface of the 
holding element (arrows), (a) Original magnification χ 56, bar 179 μ/η, φ) 
original magnification χ 140, bar 71 μτη. 
Figure 8: A thin fibrous tissue capsule surrounds the titanium fibre mesh. 
Original magnification χ 44, bar 227 μ/я. 
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Figure 9: The porosity of the fibre web structure is filled with immature fibrous 
connective tissue and bloodvessels. Original magnification χ 112, bar 89 μηι. 
6.3.3 Histomorphometric evaluation 
The results of the histomorphometric evaluation are given in table 2. The 
following observations were made: 
1) statistical analysis of the degree of epidermal downgrowth and sulcus width, 
using a nonparametric test according to Wilcoxon, showed no significant 
difference between the one- and two-stage percutaneous device. 
2) application of the histomorphometric grading scale showed no difference in 
tissue response between the two different implants. The fibre mesh was 
either surrounded by a capsule measuring one to nine fibroblasts or was 
embedded in the subdermal connective tissue without the presence of a 
fibrous capsule. In all specimens the titanium fibre mesh was filled with 
immature connective tissue. 
3) to compare the number of bloodvessels, foreign body giant cells and 
inflammatory cells present in the titanium fibre mesh of both implant types, 
the Wilcoxon rank-sum test was used. This procedure revealed that only 
significantly more foreign body giant cells were present in case of the one-
stage percutaneous device compared to the two-stage implant (p<0.05). 
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6.4 Discussion 
As described earlier, the potential clinical benefice of a two stage procedure 
for the placement of peritoneal dialysis catheters has been demonstrated by 
Moncrief and Alvaro.14·15 The present study confirms these findings. Although none 
of the experimental titanium mesh implants evoked an exit-site infection, 
significantly more one-stage implants were lost. 
This phenomenon is probably due to an incomplete healing of the 
subcutaneous tissue, resulting in an increased marsupialization process. Similar 
observations were done by Jansen in experiments with guinea pigs.16 Five weeks 
after placement of percutaneous devices in the back of these animal, all implants 
were still present. However, at six weeks all implants were lost. Preliminary killing 
of the guinea pigs, followed by histological examination of the retrieved implants 
showed that at 5 weeks extensive downwards migration of the epidermis had 
occurred. The migration was not visible clinically, as only a small part of the 
implants was exposed. This process could finally explain the loss of implants. It 
also corroborates with our observation that significantly more foreign body giant 
cells are present in the one-stage titanium fibre mesh compared to the two-stage 
implants. In earlier studies, we demonstrated that the titanium fibre mesh itself does 
not evoke this inflammatory response.25,26 Probably more transfer of stresses on 
one-stage implants causes an incomplete healing of the subcutaneous tissue, which 
finally results in an inflammatory reaction inside the fibre mesh. In light of the 
above mentioned, it is also not surprising that no differences in marsupialization 
rate, capsule thickness and quality were observed between the successful one- and 
two-stage implants. 
Further, our study showed an enhanced rate of marsupialization compared 
to earlier performed experiments in rabbits.20 This finding is in contrast with the 
findings of Ganjee et al.21 They investigated the existence of species related 
differences in percutaneous wound healing. For that purpose, they placed 
percutaneous implants, made of Dacron®, in the back of rabbits, dogs and goats. 
They observed that the marsupialization rate of rabbits was higher compared to 
goats. However, in this study, the measures to prevent the animals from 
manipulating the implants were very strict. For instance, all animals had an 
Elizabethan-collar around the neck and were individually housed. Despite the 
precautions we took for the housing of the experimental animals, it cannot be 
excluded that they were still able to manipulate their catheters. For example, since 
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the animals were stalled in a row, they could rub their flanks to each other. Human 
clinical studies already revealed that excessive manipulation results in exit-site 
infection and implant extrusion.28 This explains our observed enhanced 
marsupialization rate. 
Notwithstanding this apparently simple conclusion, it has to be mentioned 
that marsupialization is a rather complex process in which many different 
parameters are involved. For example, the wettability of the catheter material has 
been reported to influence the final tissue behavior. Already, various in vitro and 
in vivo studies demonstrated the effect of this physicochemical parameter on the 
foreign body host response.29"32 In addition, hydrophobic surfaces inhibit cell 
attachment and proliferation of fibroblasts, both processes necessary to obtain a 
healthy exit-site at the interface of skin and implant.30 Since in our experimental 
design the holding element was made of hydrophobic PCTFE, this factor can also 
have attributed to the increased marsupialization rate compared to hydrophilic 
titanium holding element as used in the earlier study. 
In summary, this study showed that the two-stage surgical procedure for 
implantation of a percutaneous device, evokes a better tissue response, compared 
to the one-stage surgical technique. Because this experiment is one step in the 
development of a peritoneal dialysis catheter provided with a titanium fibre mesh, 
clinical experiments will have to be performed to show the efficacy of the design 
and surgical procedure. 
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7.0 SUBCUTANEOUS WOUNDHEALING IN TITANIUM FIBRE MESH; 
5-10 WEEKS IMPLANTATION 
7.1 Introduction 
Peritoneal dialysis has become a first-choice initial treatment method for 
many patients with end-stage renal failure. Peritoneal dialysis has several important 
advantages over other, more conventional dialysing methods, such as: (1) fluid and 
diet allowance is less strict, (2) blood pressure is usually better controlled, (3) a rise 
in haematocrit occurs, (4) less growth retardation is noticed in children, (5) 
anticoagulant drugs are redundant, and (6) the method is cheap and relatively 
simple.13 The method of peritoneal dialysis is based on the capacity of the 
peritoneum to exchange fluid and metabolic products. To achieve this, dialysis fluid 
is instilled in the abdominal cavity through a permanent percutaneous access device. 
However, a prerequisite to maintain a percutaneous catheter successfully is 
the presence of a tight percutaneous seal in the area where this device penetrates the 
skin. Failure to obtain such a seal results in downward migration of the epidermis 
along the catheter surface, followed by infection. Therefore, considerable research 
efforts have been undertaken to develop a percutaneous device that can be 
maintained functional for long periods.4"20 The devices used mostly consisted of a 
polymeric micro- or macroporeus anchor attached to a silicone tube. The porosity 
of the anchor was supposed to allow ingrowth of connective tissue and cause 
inhibition of epithelial downgrowth along the implant surface.17-21 Nevertheless, 
almost all designs ended in failure because of a lack of maturation of the connective 
tissue, filling the pores of the used materials. 
Despite these findings, most of the currently used catheters for peritoneal 
dialysis still consist of a silicon tube with porous polyethyleneterephtalate (Dacron*) 
cuffs attached to it. Consequently, it is not astonishing that in the group of patients 
treated with peritoneal dialysis a high rate of complications, such as exit-site and 
tunnel infections, occur. Also, recurrent peritonitis is supposed to be related with 
these percutaneous access problems.3 
Considering these problems, for the last 10 years research in our laboratory 
was directed toward the development of new, more successful percutaneous 
devices.22"26 These experiments have resulted in a percutaneous device provided with 
a subcutaneous flange made of a porous sintered titanium fibre mesh structure.27 In 
addition, on basis of the described results with dental implants,28 a so-called "two-
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stage" surgical technique was used for placement of the devices. In this procedure, 
during the first session only the subcutaneous part is inserted. Subsequently, after 
an intervening healing period of three months, the percutaneous part is adapted to 
the subcutaneous component. Various animal experiments showed the efficacy of 
our device and method. For example, it has been proven that: (1) ingrowth of 
connective tissue in the micropores of the fibre mesh did take place, (2) no, or only 
very limited, epidermal downgrowth occurred after six months of implantation, and 
(3) no percutaneous exit-site infections occurred. However, for application in 
peritoneal dialysis, a 3-month period between the first and second surgical session 
is too long. Therefore, the purpose of this study was to investigate the possibility 
of reducing the duration of this intervening healing period. 
7.2 Material and methods 
7.2. / Implant materials 
Figure 1 shows the porous fibre mesh used in this experiment. The mesh 
was fabricated by interengaging and intertwining a multiplicity of commercially 
pure titanium fibres. After compression the fibre structures were sintered to bond 
the fibres at their points of contact. The fibre diameter was 50 μπι. The volumetric 
porosity was 86%, and the weight of the mesh sheet was 600 g/m2. Before use, the 
material was inspected by scanning electron microscopy and reflected light 
microscopy. In addition, the surface composition was analyzed by energy dispersive 
x-ray analysis (EDAX, Philips 525). The flexibility of the fibre mesh was 
determined as deflection per unit load in a three-point bending test as performed 
with a thermal mechanical analyzer (Mettier TMA 40). For this measurement three 
specimens were used. 
7.2.2 Implantation procedure 
Eighteen New Zealand white rabbits were used in this experiment. In each 
rabbit, six implants were placed, three on the left and three on the right side of the 
spinal column. The implants measured 2.0 χ 1.5 cm. The implants were inserted 
with intervals of one week. Consequently, at the end of the experiment, in each 
rabbit six implants were present, with implantation periods ranging from 5-10 
weeks. 
Before insertion the implants were sterilized in an autoclave. During surgery 
the animals were sedated by intramuscular injection of Hypnorm (Duphar, 
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Amsterdam) and atropine. The back of the rabbits was shaved, washed, and 
disinfected with iodine. Paravertebral, only at one side of the spinal column, a 
longitudinal incision of about 3.0 cm was made through the full thickness of the 
skin. Subsequently, lateral to the incision a subcutaneous pocket was created by 
blunt dissection with scissors. The fibre mesh was inserted in this pocket. Finally, 
the wound was carefully closed intracutaneously with vicryl 3-0. 
To assure complete randomization, the position of the various implants into 
the back was based on a split plot design.29 Balancing was done by Latin square to 
exclude experimental influences. 
Figure 1: Titanium fibre mesh implant used in the experiment. 
7.2.3 Histologic evaluation techniques 
Five weeks after the last surgical procedure the rabbits were overdosed with 
an intravenous injection of Hypnorm. After the animals were killed, the implants 
with their surrounding tissues were excised immediately and fixed in 10% buffered 
formalin. Subsequently, the tissue specimens were trimmed to remove excess tissue 
and embedded in methyl methacrylate. After polymerization thin (10 μπι) histologic 
sections were prepared using a modified diamond-blade sawing microtome 
technique.30 The sections, containing the implants and the surrounding tissues 
attached to them, were stained with methylene blue and basic fuchsin and 
investigated by light microscopy. 
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To assess the soft tissue response to the implants, both histologic and 
histomorphometric evaluations were performed. The histologic evaluation consisted 
of thorough description of the observed tissue reaction. For the histomorphometric 
evaluation the following two approaches were used: 
the characteristics of the capsule surrounding the implant and the 
characteristics of the tissue inside the interstices of the implant were rated 
according to a method that has already been described extensively in a 
previous paper (table l).3 1 In summary, the evaluation of the capsule was 
qualitative and semiquantitative, whereas the evaluation of the interstitial 
tissue was only qualitative. The semiquantitative capsule classification 
consisted of a capsule thickness measurement based on the observed number 
of fibroblasts. The qualitative rating of the capsule and interstitium 
consisted of numerically rating the tissue morphology (fibrous tissue, 
maturity, presence of connective tissue or fat tissue) and cellularity 
(presence of fibroblasts, macrophages, and giant cells), 
the tissue response was quantified by counting the number of blood vessels 
and inflammatory/foreign body cells in the surrounding fibrous capsule and 
interstitial tissue. For this purpose, the microscopic images were projected 
with a total magnification of χ 400 on a colour monitor using a colour 
camera attached to the light microscope. Subsequently, the occurrence of 
blood vessels and foreign body giant cells was calculated in 14 
predetermined fields (figure 2). Depending on the total length of the 
section, the fields were positioned at regular 2 mm intervals: six fields in 
the capsule surrounding the fibre mesh, six in the middle of the 
interstitium, and two at both ends of the interstitium. The occurrence of 
inflammatory cells in each field was estimated by superimposing a net 
ruling, consisting of 176 smaller squares (1.5 χ 1.5 cm) on the colour 
monitor. Then, the number of inflammatory cells in five marked squares 
per field was counted. 
All histomorphometric procedures were done blindly by two different 
operators. 
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Table 1. Histologic grading scale for soft-tissue implants. 
capsule 
quantitatively 
capsule 
qualitatively 
interstitium 
qualitatively 
Response 
thickness rating 
1-4 fibroblasts 
5-9 fibroblasts 
10 30 fibroblasts 
> 30 fibroblasts 
Not applicable 
capsule tissue is fibrous, mature, not dense, resembling con-
nective or fat tissue in the non injured regions 
capsule tissue is fibrous but immature, showing fibroblasts and 
little collagen 
capsule tissue is granulous and dense, containmg both fibroblasts 
and many inflammatory cells 
capsule consists of masses of inflammatory cells with little or no 
signs of connective tissue organization 
cannot be evaluated because of infection or other factors not 
necessarily related to the material 
tissue in interstitium is fibrous, mature, not dense, resembling 
connective or fat tissue in the non-injured regions 
tissue in interstitium shows blood vessels and young fibroblasts 
invading the spaces, few macrophages may be present 
tissue in interstitium shows giant cells and other inflammatory 
cells in abundance but connective tissue components in between 
tissue in interstitium is dense and exclusively of inflammatory 
type 
implant cannot be evaluated because of problems that may not 
only be related to the material to be tested 
Score 
4 
3 
2 
1 
0 
4 
3 
2 
1 
0 
4 
3 
2 
1 
0 
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Figure 2: Schematic drawing of the subcutaneous implant showing the fields of 
cell counting used in the histomorphometric analysis. 
7.3 Results 
7.3.1 Titanium fibre mesh characterization 
Scanning electron microscopic examination revealed that the surface of the 
titanium fibres was not smooth. Irregular, rather profound, longitudinal grooves 
appeared to be present on the surface of the fibre (figure 3). The ED AX inspection 
showed that the implant was composed of pure titanium. The measured flexibility 
of the mesh was 360 + 18 μΝ. 
7.3.2 Macroscopic tissue response 
Of the eighteen rabbits four animals showed an extensive Pastorella infec­
tion at some operation sites. Because the infections could interfere with the healthy 
operation-sites these animals were excluded from the study. The rest of the 
experimental animals had no wound complications and appeared to be in good 
health throughout the test period. At sacrifice, the fibre mesh implants were 
surrounded by a thin reaction-free fibrous capsule. There was no indication that the 
thickness of the capsule differed between the various implantation periods. 
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Figure 3: Scanning electron micrograph of the titanium fibres. 
Figure 4: Titanium fibre mesh implant surrounded by a thin to medium thin 
fibrous tissue capsule. A nerve bundle is lying close to the fibre web (arrow). 
Original magnification χ 50, bar 51 μτη. 
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7.3.3 Descriptive light microscopic evaluation 
Evaluation of the prepared sections revealed that, independent of the 
implantation period, the tissue response to the fibre mesh was relatively uniform. 
All implants were surrounded by a thin to medium-thin fibrous tissue capsule 
(figure 4). The capsule was usually free of inflammatory cells and contained 
fibrocytes, collagen, and blood vessels. In addition, occasionally even nerve bundles 
were observed close to the fibre mesh. 
Inside the implants, the mesh porosity was filled with components of early-
stage connective tissue including capillaries and larger blood vessels (figure 5). 
Only in some sections of the 9- and 10-week implantation period was evidence of 
more mature collagenous connective tissue observed (figure 6). Almost no 
macrophages or lymphocytes were seen inside the fibre mesh. If they were present, 
inflammatory cells were mostly at one side of the titanium fibres (figure 7). Some 
implants showed fatty tissue ingrowth (figure 8). 
Figure 5: Mesh porosity filled with components of early-stage connective 
tissue including capillaries and larger blood vessels. 
Original magnification χ 40, bar 64 urn. 
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Figure 6: More mature collagenous connective tissue was observed inside the 
fibre mesh. Original magnification χ 50, bar 51 μτη. 
> «0 %2 
Figure 7: Foreign body giant cell only at one side of the titanium fibre. 
Original magnification χ 160, bar 16 μ/η. 
131 
Subcutaneous woundhealing 
Figure 8: Fatty tissue ingrowth into the titanium fibre mesh. 
Original magnification χ 32, bar 80 urn. 
7.3.4 Histomorphometric evaluation 
Figure 9 shows the data of this histomorphometric rating of capsule and 
interstitium characteristics for all implantation periods. Statistical analysis of these 
data, using a one-way analysis of variance (ANOVA) and a multiple comparison 
procedure (Newman-Keuls), showed that no significant difference existed in both 
capsule quantity and quality between the various implantation periods (p=0.12 and 
p=0.56). In addition, no significant difference was demonstrated in interstitium 
quality between the implantation times (p=0.39). 
Figure 10 provides data on the occurrence of inflammatory and foreign 
body giant cells, as wells as blood vessels, in the fibrous capsule and interstitial 
tissue. 
For the inflammatory cells, the staining technique used, made it impossible 
to identify different populations. Very few inflammatory cells were present. One­
way ANOVA and a multiple comparison procedure (Newman-Keuls) indicated that 
a significant difference existed in the number of inflammatory cells occurring in the 
capsule and the interstitial tissue (p < 0.05). Further statistical testing revealed no 
significant difference in cell density between the various implantation periods. 
132 
£ 3 
Chapter 7 
5 weeks 6 weeks 7 weeks θ weeks 9 weeks 10 weeks 
capsule 
quantity 
capsule Ш:У::УІ interstltlum 
quality quality 
Figure 9: Comparative rating of capsule quantity, capsule quality and 
interstitium quality using the histomorphometric grading scale. 
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Figure 10: Comparative rating of (A) inflammatory cells, 
(B) foreign body giant cells and (C) blood vessels. 
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No foreign body giant cells were found in the fibrous capsule. It was 
noticed that significantly more foreign body giant cells were present at the ends than 
in the middle part of the mesh material (p<0.05). The majority of the foreign body 
giant cells showed five to twenty nuclei. Again, no significant difference in foreign 
body giant cells occurrence existed for the various implantation periods. 
Finally, in all involved tissues similar numbers of blood vessels were found. 
The diameter of the blood vessels varied from 20 to 100 μπ\. There was no 
significant influence for the implantation period in the number and size of the blood 
vessels. 
7.4 Discussion 
To increase the life expectancy of soft tissue-anchored percutaneous devices 
two problems have to be overcome: 
1. a decrease of the stress concentrations around the percutaneous exit-site 
together with a more balanced distribution of the involved forces in the 
subdermal area; and 
2. establishment of a mature connective tissue attachment contact to the 
device. 
In earlier studies, we demonstrated that the use of titanium fibre mesh as 
a subcutaneous anchor can possibly solve these problems, only, we used a "two-
phase" surgical technique with an intervening healing period of three months 
between the insertion of the subcutaneous flange and the placement of the 
percutaneous part. From a clinical point of view, this time interval is considered too 
long. Therefore, the aim of this study was to investigate the reduction of this 
period. 
The results demonstrated that there is no difference in soft tissue response 
to titanium fibre mesh implants during implantation periods ranging from five to ten 
weeks. Apparently, there is no need to wait three months to permit tissue ingrowth 
in the titanium fibre mesh material. This finding will lead to a better acceptance for 
clinical application of our percutaneous device. 
From studies performed with fabric forms of polyethyleneterephtalate and 
polytetrafluoroethylene,1018·20 it has been learned that this kind of polymeric 
materials is mainly infiltrated with macrophages and giant cells. An organized 
connective tissue does not appear. However, as indicated by the histomorphometric 
evaluations used in the present study, there is a low level of macrophage and giant 
134 
cell activity inside the titanium mesh. In addition, similar studies26 with titanium 
implants left in place for 9 months demonstrated the development of more mature 
connective tissue without significant changes in cellular population. Therefore, the 
conclusion that titanium improves the connective tissue formation appears to be 
appropriate. 
According to Steinemann32 biocompatible behaviour occurs because the 
corrosion products of titanium are at saturation in living tissue. In addition, the 
released hydroxides and oxides are electroneutral. This means that an implant made 
of titanium will never effect a local tissue reaction. Such a lack of interference is 
even independent of the implant size or total surface area. In case of other metals, 
such as stainless steel or CoCrMo alloys, the corrosion products are charged and 
not inert in tissue. This explanation for the favourable functioning of titanium also 
corroborates well with a previous study33 in which we used stainless-steel fibre 
mesh implants with varying fibre diameters. Then, as a result of the increased 
surface area, an unfavourable tissue response of the implants with a small fibre 
diameter was observed. 
Compared to titanium, the chronic inflammatory reaction to porous 
polyethyleneterephtalate and polytetrafluoroethylene subcutaneous implants can be 
related to differences in surface energetic properties. In contrast to titanium, these 
types of polymers have low surface tension values. Some authors have shown in in 
vivo and in vitro studies that biomaterials with low-energy surfaces are less 
biocompatible and influence the foreign body host response.34"37 
Considering the existing differences in tissue reaction between subcutaneous 
implant materials, two other phenomena have to be discussed. First, we noticed that 
the giant cells present inside the mesh do not surround the fibres, but are situated 
at one side. This is probably caused by interfacial stresses between tissue and metal 
fibre. Second, our earlier investigations38 indicated an additional relation between 
flexibility of the titanium mesh structure and tissue response. Considering the 
flexibility properties, it has to be noted that the mechanical trauma produced by 
movement and shape of the implant can be responsible for a different tissue 
response.39 This can explain the observed discrepancy in the number of giant cells 
found between the end and middle parts of the fibre mesh. Based on our results and 
in light of all these observations and hypotheses, it can be argued that the definitive 
effect from the connective tissue healing within porous subcutaneous implants 
cannot be described by a single parameter, but is the result of several synergistic 
135 
Subcutaneous woundhealing 
factors. 
The histomorphometric evaluation of the soft tissue response to the implants 
was based on two different methods. For the first method, a simple standardized 
grading scale, as developed in our laboratory,11 was used. For the second method, 
the cellular response to the fibre mesh was numerically quantified. This latter 
approach is more elaborative. However, the results are considered to be more 
accurate. Because the overall results with both procedures correspond, this confirms 
again that the grading scale is suitable for the tast evaluation of soft-tissue implants. 
In conclusion, the experiment has demonstrated that for titanium mesh 
percutaneous devices a five week healing period is sufficient between the installation 
of the subcutaneous and percutaneous parts. In future experiments, a possible 
further decrease of the intervening period will be investigated. 
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8.0 WOUND HEALING PHENOMENA IN TITANIUM FIBRE MESH; 
THE INFLUENCE OF THE LENGTH OF IMPLANTATION 
8.1 Introduction 
It is well known that considerable difficulties exist with the maintenance of 
percutaneous devices.1"9 The encountered problems have mainly to do with exit-site 
infections and related complications. 
Therefore, in our laboratory research has been directed toward the 
development of a more successful percutaneous device.10"14 These efforts have 
resulted in a percutaneous device provided with a subcutaneous flange made of a 
porous titanium fibre mesh structure.15 In addition to the design of the implant a so-
called two-stage surgical procedure was used for placement of the devices. During 
the first surgical session the subcutaneous component was inserted. After a healing 
period of three months, the percutaneous part of the implant was adapted to the 
subcutaneous component. Because this healing period of 3 months was considered 
to be too long for application in peritoneal dialysis an experiment has been 
performed to determine whether it is possible to reduce this period.16 For this 
purpose titanium fibre meshes were inserted subcutaneously in rabbits with 
implantation periods ranging from 5 till 12 weeks. Histological and 
histomorphometrical analysis of the tissue response to the implants showed that 
there was no difference between the various implantation periods. Considering these 
results, further reduction of the healing period has to be considered. The purpose 
of this experiment was to analyze the tissue response to the titanium fibre structures 
with implantation periods varying from 1 till 6 weeks. 
8.2 Material and methods 
8.2.1 Implant materials 
Figure 1 shows the porous fibre mesh used in this experiment. The mesh 
was fabricated by interengaging and intertwining a multiplicity of commercially 
pure titanium fibres. After compression the fibre structures were sintered to bond 
the fibres at their points of contact. The fibre diameter was 50 μητι. The volumetric 
porosity was 86%, and the weight of the mesh sheet was 600 g/m2. 
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Figure 1: Titanium fibre mesh implant used in the experiment. 
8.2.2 Implantation procedure 
Nine healthy, adult (2-3 years of age), female Saane goats weighing about 
60 kg were used in the experiments. In each goat, six implants were placed, three 
on the left and three on the right side of the spinal column. The implants measured 
2.0 χ 1.5 cm. The implants were inserted with intervals of one week. 
Consequently, at the end of the experiment, in each goat six implants were present, 
with implantation periods ranging from 1-6 weeks. 
Before insertion the implants were sterilized in an autoclave. Surgery was 
performed under local anaesthesia. The back of the goats was shaved, washed, and 
disinfected with iodine. Paravertebral, only at one side of the spinal column, a 
longitudinal incision of about 3.0 cm was made through the full thickness of the 
skin. Subsequently, lateral to the incision a subcutaneous pocket was created by 
blunt dissection with scissors. The fibre mesh was inserted in this pocket. Finally, 
the wound was carefully closed with vicryl 3-0. 
To assure complete randomization, the position of the various implants into 
the back was based on a split plot design.14 Balancing was done by Latin square to 
exclude experimental influences. 
142 
8.2.3 Histologie evaluation techniques 
One week after the last surgical procedure the animals were sacrificed using 
an overdose of Nembutal®. After the animals were killed, the implants with their 
surrounding tissues were excised immediately and fixed in 10% buffered formalin. 
Then the tissue specimens were trimmed to remove excess tissue and embedded in 
methyl methacrylate. After polymerization thin (10 μπι) histologic sections were 
prepared using a modified diamond-blade sawing microtome technique.1718 The 
sections, containing the implants and the surrounding tissues attached to them, were 
stained with methylene blue and basic fuchsin and investigated by light microscopy. 
To assess the soft tissue response to the implants, both histologic and 
histomorphometric evaluations were performed. The histologic evaluation consisted 
of thorough description of the observed tissue reaction. For the histomorphometric 
evaluation the following parameters were assessed: 
the characteristics of the capsule surrounding the implant and the 
characteristics of the tissue inside the interstices of the implant as rated 
according to a method that has already been described extensively in a 
previous paper (table l). 1 9 In summary, the evaluation of the capsule was 
qualitative and semiquantitative, whereas the evaluation of the interstitial 
tissue was only qualitative. The semiquantitative capsule classification 
consisted of a capsule thickness measurement based on the observed number 
of fibroblasts. The qualitative rating of the capsule and interstitium 
consisted of numerically rating the tissue morphology (fibrous tissue, 
maturity, presence of connective tissue or fat tissue) and cellularity 
(presence of fibroblasts, macrophages, and giant cells). 
the tissue response as quantified by counting the number of blood vessels 
and inflammatory/foreign body cells in the surrounding fibrous capsule and 
interstitial tissue. For this purpose, the microscopic images were projected with a 
total magnification of χ 400 on a colour monitor using a colour camera attached to 
the light microscope. Subsequently, the occurrence of blood vessels and foreign 
body giant cells was calculated in 14 predetermined fields (figure 2). Depending on 
the total length of the section, the fields were positioned at regular 2 mm intervals: 
six fields in the capsule surrounding the fibre mesh, six in the middle of the 
interstitium, and two at both ends of the interstitium. The occurrence of 
inflammatory cells in each field was estimated by superimposing a net ruling, 
consisting of 176 smaller squares (1.5 χ 1.5 cm) on the colour monitor. Then, the 
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number of inflammatory cells in five marked squares per field was counted. 
All histomorphometric procedures were done blindly by two different 
operators. 
Table 1. Histologic grading scale for soft-tissue implants. 
capsule 
quantitatively 
capsule 
qualitatively 
interstitium 
qualitatively 
Response 
thickness rating 
1-4 fibroblasts 
5-9 fibroblasts 
10-30 fibroblasts 
> 30 fibroblasts 
Not applicable 
capsule tissue is fibrous, mature, not dense, resembling con-
nective or fat tissue in the non-injured regions 
capsule tissue is fibrous but immature, showing fibroblasts and 
little collagen 
capsule tissue is granulous and dense, containing both fibroblasts 
and many inflammatory cells 
capsule consists of masses of inflammatory cells with little or no 
signs of connective tissue organization 
cannot be evaluated because of infection or other factors not 
necessarily related to the material 
tissue in interstitium is fibrous, mature, not dense, resembling 
connective or fat tissue in the non-injured regions 
tissue in interstitium shows blood vessels and young fibroblasts 
invading the spaces, few macrophages may be present 
tissue in interstitium shows giant cells and other inflammatory 
cells in abundance but connective tissue components in between 
tissue in interstitium is dense and exclusively of inflammatory 
type 
implant cannot be evaluated because of problems that may not 
only be related to the material to be tested 
Score 
4 
3 
2 
1 
0 
4 
3 
2 
1 
0 
4 
3 
2 
1 
0 
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implant 
capsule 
field of measurement 
field of measurement 
Figure 2: Schematic drawing of the subcutaneous implant showing the fields 
of cell counting used in the histomorphometric analysis. 
8.3 Results 
5.3.1 Descriptive light microscopic evaluation 
Evaluation of the prepared sections showed that the tissue reaction to the 
titanium meshes with an implantation period of 1 week, was mainly characterized 
by an inflammatory response. The implants were surrounded by a thick tissue 
capsule containing inflammatory cells and bloodvessels (figure 3). Inside the 
porosity of the mesh mainly inflammatory cells were observed, although also some 
fibroblasts were present (figure 4). Occasionally, accumulations of erythrocytes 
were found inside the mesh. Already at 2 weeks of implantation the inflammatory 
response in both the tissue capsule and interstitium decreased. Instead highly 
cellular fibrous tissue with bloodvessels was observed. Furthermore the thickness 
of the surrounding tissue capsule was reduced. 
The tissue response to the fibre meshes with an implantation period of 3 till 
6 weeks was relatively uniform (figure 5). These implants were surrounded by a 
medium thin fibrous tissue capsule containing fibroblasts, collagen, bloodvessels and 
some inflammatory cells. Occasionally nerve bundles were observed close to the 
mesh material. Inside the implants, the mesh porosity was filled with components 
of early-stage connective tissue including bloodvessels (figure 6). 
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Figure 3: At one week implantation, the capsule surrounding the titanium fibre 
mesh mainly consists of inflammatory cells and bloodvessels. 
Original magnification χ 25, bar 122 \un. 
Figure 4: Inside the porosity of the mesh, inflammatory cells and 
bloodvessels are present after one week implantation. 
Original magnification χ 63, bar 49 μχη. 
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Figure 5: After 2 weeks implantation, the tissue capsule mainly consists of 
fibroblasts and collagen. The inflammatory response together with the number 
of bloodvessels decreased. Original magnification χ 25, bar 122 μ/η. 
ι 
ЯлА 
Figure 6: Inside the mesh material early stage connective tissue is present at 3 
weeks implantation. Original magnification χ 63, bar 49 μ/η. 
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8.3.2 Histomorphometric evaluation 
Figure 7 shows the data of the histomorphometric rating of capsule and 
interstitium characteristics for all implantation periods. Statistical analysis of these 
data, using a one-way analysis of variance (ANOVA) and a multiple comparison 
procedure (Newman-Keuls), showed that a significant difference existed in capsule 
quantity between 1 week and 3 to 6 weeks implants (p<0.01). In addition, a 
significant difference was demonstrated in capsule and interstitium quality between 
1 week and 2 to 6 weeks specimens (p<0.01 and ρ < 0.01). 
Figure 8 provides data on the occurrence of inflammatory and foreign body 
giant cells, as wells as blood vessels, in the fibrous capsule and interstitial tissue. 
One-way ANOVA and a multiple comparison procedure (Newman-Keuls) indicated 
that a significant difference existed in the number of inflammatory cells occurring 
in the middle of the interstitial tissue between an implantation period of 1 week 
compared to 3 till 6 weeks (p<0.01). 
For all implantation periods, no foreign body giant cells were found in the 
fibrous capsule. Although it appeared that at 1 week of implantation less giant cells 
were present in the interstitium, no significant difference in foreign body giant cells 
occurrence existed for the various implantation periods. 
Statistical analysis of the blood vessel data revealed that there was no 
significant influence of the implantation period on the number of the blood vessels 
in both capsule and interstitium. The diameter of the blood vessels varied from 5 
to 100 μτη. 
Finally, the number of inflammatory cells, foreign body giant cells and 
blood vessels present in the middle part of the mesh material compared to the 
endings of the interstitium was not significantly different. 
8.4 Discussion 
The success of implanted biomaterials is dependent on many factors, which 
all have to do with the final tissue response to the materials. In the cascade of 
events that follow after the first injury to insert a material, the duration and level 
of the initial inflammatory response play an important role. With regard to the used 
implant material, the possibility of evoking an adverse healing response depends on 
material variables like bulk chemistry, surface texture and implant design.20,21 In this 
context it has to be emphasized that titanium is considered to be a very 
biocompatible material.22 Therefore, it is not surprising that the overall healing 
148 
, Chapter 8 
1 week 2 weeks 3 weeks 4 weeks 5 weeks 6 weeks 
capsule 
quantity 
capsule 
quality 
I'-i'-'-vJ interstitium 
quality 
Figure 7: Comparative rating of capsule quantity, capsule quality and 
interstitium quality using the histomorphometric grading scale. 
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Figure 8: Comparative rating of (A) inflammatory cells, (B) foreign body giant 
cells and (C) blood vessels. 
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process to the titanium fibre mesh, as used in this study, shows a striking similarity 
with the regular sequence in all connective tissue wound healing processes.23"25 
Although the exact time depends on the original tissue location, the initial 
inflammatory and proliferative phase of wound healing take about 2 weeks, 
followed by a remodelling phase. The histomorphometric evaluation of the soft 
tissue response to the titanium fibre mesh material, as used in the present study, 
showed that during the first 2 weeks after implantation mainly inflammation 
occurred around the implants. When this inflammatory response faded away, 
fibroblasts started to proliferate. This was followed by the deposition of collagen 
inside the titanium mesh. Unfortunately, the used histological preparation technique 
makes it impossible to obtain additional information about the quality of the 
produced collagen matrix. 
Considering our previous study in rabbits,16 dealing with the healing 
response between 5 and 10 weeks, we now observed nò difference between the 
number of foreign body giant cells as found in the end and the middle interstitium 
parts. Two explanations can be given for this discrepancy in observations. First, it 
is possible that the implantation period is too short to result in a different reaction. 
Certainly, when realised that mechanical trauma, as a product of the flexibility 
properties of the implant, is held responsible for the adverse reaction at the ends of 
the mesh implants.26,27 Second, the implantation site as used in this goat study is 
more flattened than in the previous rabbit study, consequently resulting again in less 
mechanical trauma. 
Finally, comparison of our goat and rabbit study learns that with the applied 
histomorphometrical techniques no gross differences can be demonstrated between 
3 till 6 and 5 till 10 week healing periods. 
Therefore, on basis of the results we conclude that the intervening healing 
period between the first and second stage surgical procedure for placement of our 
experimental titanium mesh percutaneous device can be reduced to 3 weeks. This 
observation can lead to a better clinical acceptance of this device for human 
applications like peritoneal dialysis. 
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9.0 CONCLUSIONS 
Patients with end-stage renal failure can be treated with peritoneal dialysis. 
The method of peritoneal dialysis is based on the capacity of the peritoneum to 
exchange fluid and metabolic products. To achieve this dialysis fluid has to be 
instilled in the abdominal cavity through a permanent percutaneous dialysis catheter. 
Unfortunately, the efficacy peritoneal dialysis is hampered by severe problems 
related to the access of the peritoneal cavity. Both infection of the percutaneous 
exit-site of the catheter and peritonitis are serious complicating factors, often 
resulting in discontinuation of peritoneal dialysis. Furthermore, a relationship is 
supposed between recurrent peritonitis and access problems.1 
As demonstrated in this study, the use of titanium fibre mesh material has 
a great potential for application in CAPD catheters. Still some questions have 
arisen, which will be discussed first. 
9.1 Unresolved topics 
Although, this study showed that the experimental percutaneous devices 
prevented epidermal migration, our experiments did not establish the need of a 
subcutaneous anchor design to eliminate motion at the exit-site. Considering the 
overall observed tissue reaction to titanium fibre mesh, the importance of an anchor 
design can even be questioned. In this context, it has to be stressed that when 
indeed can be proven that similar results can be obtained with a cuff design, the 
acceptance by clinicians of our experimental catheter would be facilitated. For 
example, application of a proximal titanium cuff, in design similar to the nowadays 
used Dacron® cuff, allows: 
the use of laproscopical techniques for the insertion of the catheters. 
the use of a simple two-stage procedure based on the method of Moncrief.2 
In this technique, the percutaneous part of the catheter is buried 
subcutaneously. After a healing period of 3-5 weeks, the percutaneous part is 
exteriorized. 
Another important question is whether the final success of CAPD catheters 
can further be improved by replacing the Dacron® peritoneal cuff by a titanium 
mesh cuff. In Chapter 4 of this thesis, we studied the soft tissue response to 
Dacron® velour and titanium mesh. More inflammatory cells and less collagenous 
tissue were found in the Dacron® velour. In the second chapter of this thesis, we 
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studied the access problems of patients on CAPD. The catheters were provided with 
two Dacron® cuffs. A correlation between the occurrence of peritonitis and exit-site 
infections was found. Under the assumption, that soft tissue behaviour to Dacron® 
velour is independent on the implant location, combination of our results indicate 
that this relationship can be additionally due by the adverse tissue reaction to the 
peritoneal Dacron® cuff. Consequently, it can also be suggested that the use of 
titanium mesh peritoneal cuffs will reduce this problem. 
A final question has to do with the surface topography of the titanium fibres 
as used for the mesh material. When implants are placed into the human body, they 
cause a chronic tissue reaction. This characterized by the formation of a fibrous 
tissue capsule around the implant. This capsule does not adhere to the implant 
surface. It allows a certain relative motion between the implant and the surrounding 
tissue. This mobility increases the accumulation of inflammatory cells in the 
interface capsule-implant. Sooner or later this process results in clinical problems. 
This is especially true for implants in contact with soft tissues. 
An implant would be better anchored in the surrounding tissue, when 
"adhesive attachment" of soft tissue to the implant surface could be obtained. 
Consequently, no chronic inflammatory capsule will develop. 
It is not clear under what conditions connective tissue will adhere to an 
implant surface. A factor considered of importance, is the surface microtopography 
of the used implant. For example, it has been demonstrated that parallel surface 
microgrooves with a depth of 0.5 μπι and a width of 2-5 μτη can influence 
fibroblast behaviour.35 As the titanium mesh fibres are provided with parallel 
grooves of about the same dimensions, the question that the favourable tissue 
response to the titanium mesh is caused by this surface texture, suggests itself. 
Therefore, there is a definite need for more extensive research into the biomaterial 
parameters involved in soft tissue reaction. 
9.2 Final conclusions 
Supported by the experimental results this thesis has established that: 
1 The application of Dacron velour® for anchorage of a percutaneous 
device/dialysis catheter should be reconsidered because of lack of connective 
tissue ingrowth leading to lack of stabilization of the catheter. 
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2 In contrast to Dacron® velour, titanium fibre mesh evokes good biocompatible 
behaviour characterized by the presence of small numbers of inflammatory cells 
and collagenous connective tissue. 
3 The design of the percutaneous device together with the two-stage surgical 
procedure for implantation of the implant are of major influence on the 
longterm success of the devices. 
9.3 Future perspectives 
The results lead to the following recommendations for further research: 
1 A study to the effect of replacement of the Dacron® velour cuffs of the 
Tenckhoff catheter with titanium fibre mesh cuffs. 
2 A clinical trial in peritoneal dialysis patients to the clinical efficacy of titanium 
fibre mesh provided dialysis catheters. 
3 Development of the use of percutaneous device provided with a titanium fibre 
mesh, in other medical applications like for instance percutaneous endoscopic 
gastrotomy or glucose monitoring in diabetic patients. 
4 Investigation to the additional effect of surface texturing on the tissue response 
to percutaneous devices in terms of epidermal migration, connective tissue 
attachment and inflammatory cell response. 
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SUMMARY 
A percutaneous implant can be defined as an object, made from a synthetic 
material, that permanently penetrates through a surgically created skin defect. A 
limiting factor for the extended use of percutaneous devices is that most implants 
fail over prolonged periods of implantation. The most common failure modes are 
marsupialization, permigration and infection. As all of these failure modes are 
related to the skin reaction to the implant, the formation of a stable skin-implant 
junction in the area where the implant protrudes through the skin may be the major 
factor in determining the success of percutaneous devices. 
Two different factors, either alone or together, are considered to be 
responsible for the formation and maintenance of an effective skin/implant seal: 
(1) chemical and physical properties of the implant materials 
(2) mechanical stresses, generated at the percutaneous implant-skin 
interface by the relative movement between implant and skin. 
In this thesis a study is described, focused on the clinical improvement of 
percutaneous access devices by using a sintered titanium fibre mesh for the 
subcutaneous fixation of the implants. 
Chapter 2 gives a description of the access problems of patients on CAPD 
as found at the Department of Medicine, Division of Nephrology, University 
Hospital, Nijmegen, The Netherlands. In the performed retrospective and 
prospective study, the overall rates of exit-site infections and peritonitis are 
respectively 0.80 and 1.36 infection episodes per patient-year. Furthermore, it 
appears that exit-site infections and peritonitis are the main reasons for 
discontinuation of dialysis and removal of the catheter. A correlation between the 
occurrence of peritonitis and exit-site infections is found. Also, the efficacy of the 
antibiotic treatment necessary to control these infectious complications is described. 
It is concluded that the design and the materials used to manufacture the currently 
used access device, are probably the main reason for the existing morbidity in 
peritoneal dialysis. 
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In chapter 3, an in vivo experiment is described, in which the corrosion 
behaviour of titanium and stainless steel 316L fibre meshes under various 
circumstances is determined. It appears that the effect of mechanical stress on 316L 
mesh resulted in a significant increase in the concentration of corrosion products 
compared to the unloaded situation. Furthermore, the mesh fibre diameter has a 
significant influence. In contrast to 316L, for titanium mesh no ions could be 
detected in all test conditions applied. Therefore it was concluded that the chemical 
properties of fibre mesh implant material, together with the ability to release toxic 
ions, are important determinants of their final tissue behaviour. 
In chapter 4 a histological and histomorphometrical study is presented on 
the subcutaneous tissue reaction to the Dacron® velour cuff of the currently used 
peritoneal dialysis catheter versus the experimental titanium fibre mesh. Implants, 
provided with either Dacron® or titanium mesh, were placed subcutaneously in the 
dorsum of goats. The implants were left in situ for 4 months. Histological and 
histomorphometrical evaluations were performed. It was found that the soft tissue 
response inside the Dacron® was mainly inflammatory while the titanium mesh 
evoked good biocompatible behaviour. It was concluded that the limited fibrous 
tissue ingrowth into the Dacron® cuff has to be the reason for the observed high 
failure incidence of percutaneous devices made from this material. 
Chapter 5 describes a study in rabbits on the tissue reaction to experimental 
percutaneous devices, consisting of the titanium fibre mesh. The implants were 
inserted in the backs of rabbits. The surgical procedure was performed in two steps: 
insertion of the subcutaneous part of the implants and, after 3 months, fixation of 
the percutaneous part into the subcutaneous component. Two and 6 months after 
insertion, the animals were sacrificed and the implants, with their surrounding 
tissues, were processed histologically. Light microscopic analysis demonstrated that 
only one implant showed considerable skin retraction in the percutaneous area. 
Around the rest of the implants no downgrowth or only a very limited epidermal 
downgrowth was observed. Furthermore, the fibre mesh material showed a good 
biocompatible behaviour. These results show that sintered titanium fibre-web 
structures are effective for the stabilization of percutaneous devices located in soft 
tissues and can improve their performance. 
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In chapter 6, the surgical technique to insert the titanium mesh 
percutaneous device is evaluated. Special attention is given to the possibility of 
inserting the device in a one-stage surgical procedure. Therefore, so-called one-
stage and two-stage percutaneous devices were inserted in the flanks of goats. In 
each goat, one one-stage and one two-stage implant were placed. During the 
experiments, it was observed that significantly more one-stage devices were 
extruded. Four months after the second surgical session, all maintained implants 
with their surrounding tissues were retrieved for light microscopic and 
histomorphometric analysis. No difference in epidermal downgrowth and sulcus 
width was demonstrated between the two types of implants. Furthermore, the fibre 
mesh was surrounded by a thin fibrous capsule free from inflammatory cells. Inside 
the fibre mesh structure, connective tissue was present with only scattered foci of 
inflammatory cells. An enhanced inflammatory tissue response was found inside the 
titanium mesh of one-stage compared to two-stage implants. In conclusion, this 
study showed that the two-stage surgical procedure for implantation of a 
percutaneous device performed better compared to the one-stage surgical technique. 
In chapter 7, the length of the intervening healing period between the first 
and second surgical procedure is investigated. Therefore, titanium fibre implants 
were inserted in the backs of rabbits. In each rabbit, six implants were placed with 
intervals of one week. Consequently, at the end of the experiment, in each rabbit 
six implants were present with implantation periods ranging from 5-10 weeks. After 
ten weeks, the animals were sacrificed and the implants with their surrounding 
tissues were processed histologically. Light microscopic and histomorphometric 
analysis demonstrated, that there was no difference in tissue response between the 
various implantation periods. Furthermore, it was found that the fibre mesh material 
showed good biocompatible behaviour. In conclusion, the experiment demonstrated 
that for titanium mesh percutaneous devices a five week healing period is sufficient 
between the installation of the subcutaneous and percutaneous parts. 
Chapter 8 describes the subcutaneous tissue reaction to the titanium fibre 
meshes in goats with an implantation period varying from 1 till 6 weeks. The 
implants were inserted in the backs of goats. In each goat, six implants were placed 
with intervals of one week. At the end of the experiment, in each goat six implants 
were present with implantation periods ranging from 1-6 weeks. Finally, the 
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animals were sacrificed and the implants with surrounding tissue were processed 
histologically. Analysis demonstrated, that during the first 2 weeks an inflammatory 
response was present. Thereafter, no difference in tissue response was found 
between the various implantation periods. It was concluded that, for titanium mesh 
percutaneous devices, a three week healing period between the installation of the 
subcutaneous and percutaneous part is adequate. 
The most important conclusions of this thesis are summarized in chapter 
9. Furthermore, several new questions and recommendations for future research are 
discussed. 
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SAMENVATTING 
Een percutaan implantaat kan gedefinieerd worden als een object, 
gefabriceerd van een synthetisch materiaal, dat blijvend de huid penetreert door een 
chirurgisch gecreëerde opening. De beperkende factor voor toepassing van een 
percutaan implantaat is dat de meeste implantaten uiteindelijk mislukken bij een 
langere implantatie duur. Marsupialisatie, permigratie en infectie zijn hierbij de 
meest voorkomende oorzaken. Daar deze mechanismen allen gerelateerd zijn aan 
de weefselreaktie van de huid ten opzichte van het implantaat, is de vorming van 
een stabiele afsluiting ter plaatse, waarschijnlijk de bepalende factor voor het succes 
van percutané implantaten. 
Twee verschillende factoren, apart of samen, worden verantwoordelijk 
geacht voor de vorming en behoud van een effectieve huid/implantaat afdichting: 
(1) de chemische en fysische eigenschappen van het materiaal waaruit het 
implantaat is vervaardigd en 
(2) mechanische belastingen, ontstaan ter plaatse van de verbinding tussen 
percutaan implantaat en huid als gevolg van relatieve bewegingen. 
In dit proefschrift wordt een studie beschreven, gericht op de verbetering 
van klinisch toegepaste percutané implantaten door gebruik te maken van gesinterd 
titanium vezelgaas voor de subcutane fixatie van deze implantaten. 
Hoofdstuk 2 beschrijft de problemen, gerelateerd aan de toegang tot de 
buikholte, bij peritoneaal dialyse patiënten die behandeld werden cq worden door 
de vakgroep Inwendige Geneeskunde, afdeling Nierziekten in het Academisch 
Ziekenhuis Nijmegen. In deze retrospectieve and prospectieve studie waren de 
gemiddelde incidenties van huidpoort infecties en peritonitiden respectievelijk 0.80 
en 1.36 infectie-perioden per patienten-jaar. Verder bleek dat deze huidpoort 
infecties en peritonitiden de belangrijkste redenen waren om peritoneaal dialyse te 
onderbreken cq te staken en de dialyse catheter te verwijderen. Een correlatie tussen 
het ontstaan van peritonitis en de aanwezigheid van een huidpoort infectie werd 
aangetoond. Eveneens werd de efficiëntie van antibiotische therapie, noodzakelijk 
voor de behandeling van de infectieuze complicaties, geëvalueerd. Het ontwerp van, 
en de materialen waaruit de dialyse catheter bestaat zijn waarschijnlijk 
verantwoordelijk voor de infectieuze complicaties bij peritoneaal dialyse. 
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In hoofdstuk 3 wordt een in vivo experiment beschreven, waarin het 
corrosie gedrag van titanium en roestvrij staal 316L vezelgaas onder verschillende 
omstandigheden is bepaald. Mechanische belasting van het 316L vezelgaas bleek, 
in vergelijking met de "unloaded" situatie, een significante verhoging van de 
concentratie corrosie producten te geven. Verder had de vezel diameter een 
significante invloed op het corrosie gedrag. Titanium ionen konden, in tegenstelling 
tot 316L, niet worden gedetecteerd onder de verschillende test condities. 
Geconcludeerd kan worden dat de chemische eigenschappen van het implantatie 
materiaal, tesamen met het vermogen van het materiaal om toxische ionen te 
produceren, in belangrijke mate het uiteindelijke weefsel gedrag bepalen. 
In hoofdstuk 4 wordt de subcutane weefselreaktie van Dacron®, gebruikt 
in de huidige peritoneaal dialyse catheter, ten opzichte van het titanium vezelgaas 
vergeleken met behulp van histologische en histomorphometrische parameters. 
Hiertoe werden implantaten, voorzien van Dacron® of titanium vezelgaas, subcutaan 
geplaatst in de flanken van geiten. De implanten werden 4 maanden in situ gelaten. 
Histologische en histomorphometrische evaluaties werden verricht. De 
weefselreaktie in Dacron® had met name een inflammatoir karakter terwijl titanium 
biocompatibel gedrag vertoonde. De beperkte fibreuze weefselingroei in de Dacron® 
cuff is waarschijnlijk de belangrijkste oorzaak voor het frequent falen van percutané 
implantaten vervaardigd van dit materiaal. 
Hoofdstuk 5 beschrijft de weefselreaktie op een percutaan implantaat, 
uitgerust met titanium vezelgaas in konijnen. De implantaten werden geplaatst in de 
rug van de konijnen. De chirurgische procedure bestond uit twee stappen: plaatsing 
van het subcutane deel van de implantaten en, na 3 maanden, fixatie van het 
percutané deel in het subcutane gedeelte. Twee en 6 maanden na plaatsing werden 
de dieren opgeofferd en de implantaten met omringend weefsel, verwerkt voor 
histologie. Licht microscopische analyse toonde slechts één implantaat met 
aanzienlijke huid retractie in het percutané gebied. Rondom de andere implantaten 
werd geen of zeer beperkte migratie van de epidermis gezien. Het titanium 
vezelgaas liet biocompatibel weefselgedrag zien. Deze resultaten laten zien dat 
gesinterd titanium vezelgaas een goede stabilisator is voor percutané implantaten 
geplaatst in zachte weefsel. 
168 
Samenvatting 
In hoofdstuk 6 wordt de chirurgische techniek voor implantatie van een 
titanium vezelgaas percutaan implantaat geëvalueerd. Hierbij wordt gelet op de 
mogelijkheid om het implantaat middels een één-fase chirurgische procedure te 
plaatsen. Een-fase en twee-fase implantaten werden geplaatst in de flanken van 
geiten. In elke geit werd 1 een-fase en 1 twee-fase implantaat geplaatst. Tijdens het 
experiment bleek dat significant meer een-fase implantaten werden afgestoten. Vier 
maanden na de tweede chirurgische sessie werden alle implantaten met omgevend 
weefsel verwijderd voor licht microscopische en histomorphometrische analyse. 
Tussen de twee typen implantaten werd geen verschil gevonden in epidermale 
migratie en sulcus breedte. Het vezelgaas werd omgeven door een dun fibreus 
kapsel zonder ontstekings cellen. In het vezelgaas was bindweefsel aanwezig met 
enkele groepjes ontstekings cellen. Een verhoogde ontstekingsreaktie werd in de 
een-fase implantaten gevonden in vergelijking met de twee-fase implantaten. 
Geconcludeerd kan worden dat de twee-fase chirurgische techniek voor implantatie 
van percutané implantaten te verkiezen is boven een één-fase chirurgische techniek. 
In hoofdstuk 7 wordt de lengte van de inhelingsperiode tussen de eerste en 
tweede chirurgische procedure onderzocht. Hiertoe werden titanium vezelgaas 
implantaten subcutaan geplaatst in de rug van konijnen. In elk konijn werden zes 
implantaten geplaatst met een interval van 1 week. Aan het einde van het 
experiment had elk konijn zes implantaten met implantatietijden van 5 tot 10 weken. 
Na tien weken werden de proefdieren opgeofferd waarna de implantaten met 
omringend weefsel voor histologische bewerking werden verwijderd. Licht 
microscopische en histomorphometrische analyse liet geen verschil in weefselreactie 
zien tussen de verschillende implantatieperioden. Verder liet dit experiment zien dat 
het vezelgaas een goede biocompatibele weefsel reactie vertoonde. Geconcludeerd 
kan worden dat, voor plaatsing van percutané implantaten uitgerust met titanium 
vezelgaas, 5 weken inheling tussen de eerst en tweede fase van de chirurgische 
implantatie procedure afdoende is. 
Hoofdstuk 8 beschrijft de subcutane weefsel reactie op titanium vezelgaas 
in geiten met een implantatie periode variërend van 1 tot 6 weken. Zes implantaten 
werden subcutaan geplaatst in de flanken van geiten met een interval van 1 week. 
Aan het einde van het experiment had iedere geit zes implantaten met implantatie 
perioden van 1 tot 6 weken. Uiteindelijk werden de geiten opgeofferd en de 
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implantaten met omringend weefsel bewerkt voor histologie. Gedurende de eerste 
twee weken was er sprake van een inflammatoire reactie in en rondom het 
implantaat. Daarna werd geen verschil meer gezien in weefsel reactie tussen de de 
resterende implantatie perioden. Op basis van deze resultaten werd geconcludeerd 
dat een inhelingsperiode van 3 weken afdoende is tussen het plaatsen van het 
subcutane en percutané deel van het titanium vezelgaas percutaan implantaat. 
De belangrijkste conclusies van dit proefschrift zijn samengevat in 
hoofdstuk 9. Verder wordt aandacht besteed aan nieuwe vraagstukken, onstaan naar 
aanleiding van dit proefstuk, waarbij suggesties voor verder onderzoek worden 
gegeven. 
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Titanium fibre mesh anchorage for percutaneous devices 
applicable for peritoneal dialysis 
Nijmegen 11 september 1996 
Yvonne C.G.J. Paquay 
Stellingen 
1 De aanwezigheid van één of meerdere huidpoort infecties in de medische 
voorgeschiedenis van pentoneaal dialyse patiënten predisponeert tot het 
krijgen van een peritonitis (Dit proefschrift) 
2 In tegenstelling tot titanium vezelgaas kenmerkt de weefsel reaktie in 
Dacron® velour, onder andere toegepast in pentoneaal dialyse catheters, 
zich door een inflammatoir karakter (Dit proefschrift) 
3 Een twéé-rase chirurgische techniek voor het plaatsen van een pentoneaal 
dialyse catheter, verdient de voorkeur boven een één-fase chirurgische 
methode (Du proefschrift) 
4 Indien titanium vezelgaas wordt gebruikt voor de stabilisering van een 
percutaan implantaat in zachte weefsels, zal een inhelingspenode van 3 
weken afdoende zijn tussen de eerste en de tweede chirurgische fase van 
plaatsing van dit implantaat (Dit proefschrift) 
5 Daar het aantal patiënten dat in aanmerking komt voor een nierfunctie 
vervangende therapie als pentoneaal dialyse toeneemt, zal de vraag naar een 
klinisch functioneel en infectie arm" percutaan implantaat blijven bestaan 
(Dit proefschrift) 
6 Ik hoop dat mijn zeilmaatjes na vandaag een deel van hun zeilers-jargon 
kunnen herzien van man overboord" naar "help, de doctor verzuipt' 
7 Hoewel de WHO het wereldwijd propageert, wordt de Nederlandse 
gezondheidszorg steeds meer gekort op 'Borst-voeding' 
8 Nothing is either good or bad, but thinking makes it so 
William Shakespeare 
9 Oraal functioneren en functioneel opereren zijn goed te combineren 
10 BIJ wetenschappelijk onderzoek waarbij gebruik wordt gemaakt van 
proefdieren, tracht men eerder de kool dan de geit te sparen 



